

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Rational maternal micronutrient supplementations is still a burning issue for public health: based on a large-scale cross-sectional survey of Northwestern China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028843
Article Type:	Research
Date Submitted by the Author:	27-Dec-2018
Complete List of Authors:	<p>Liu, Danmeng; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Cheng, Yue; Xi'an Jiaotong University Health Science Center, Department of Nutrition Dang, Shaonong; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Wang, Duolao; Liverpool University, Liverpool School of Tropical Medicine Zhao, Yaling; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Li, Chao; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Li, Shanshan; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Lei, Fangliang; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Qu, Pengfei; Northwest women's and children's Hospital, Translational Medicine Center Mi, Baibing; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Zhang, Ruo; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Li, Jiamei; Department of Emergency Medicine, the Second Affiliated Hospital, Xi'an Jiaotong University, Department of Emergency Medicine Zeng, L; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Yan, H; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics; Nutrition and Food Safety Engineering Research Center of Shaanxi Province</p>
Keywords:	Micronutrient supplementation, Pregnancy, Prevalence, Initiation time of use, Total use days, Associated-factors

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Rational maternal micronutrient supplementations is still a burning issue for public health:**
4
5 **based on a large-scale cross-sectional survey of Northwestern China**
6
7
8
9

10 Danmeng Liu¹, Yue Cheng², Shaonong Dang¹, Duolao Wang³, Yaling Zhao¹, Chao Li¹, Shanshan
11 Li¹, Fangliang Lei¹, Pengfei Qu⁴, Baibing Mi¹, Ruo Zhang¹, Jiamei Li⁵, Lingxia Zeng¹*, Hong Yan¹
12
13
14

15 6 7 *
16
17
18
19
20

21 ¹Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong
22 University Health Science Center, No. 76 Yanta West Road, Xi'an, Shaanxi, 710061, China
23
24

25
26 ²Department of Nutrition, School of Public Health, Xi'an Jiaotong University Health Science Center,
27 No. 76 Yanta West Road, Xi'an, Shaanxi, 710061, China
28
29

30
31 ³Liverpool School of Tropical Medicine, Liverpool University, Pembroke Place, Liverpool, L3 5QA,
32 UK
33
34

35
36 ⁴Translational Medicine Center, Northwest women's and children's Hospital, No. 1616 Yanxiang
37 Road, Xi'an, Shaanxi, 710061, China
38
39

40
41 ⁵Department of Emergency Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University,
42 No. 157 West Fifth Road, Xi'an, Shaanxi, 710004, China
43
44

45
46 ⁶Nutrition and Food Safety Engineering Research Center of Shaanxi Province, Xi'an, Shaanxi,
47 710061, China
48
49

50
51 ⁷Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry
52 of Education, Xi'an, Shaanxi, 710061, China
53
54

55
56
57 *Corresponding author:
58
59
60

1
2
3 Lingxia Zeng, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China. Fax
4
5 +86 29 82655104, email tjzlx@mail.xjtu.edu.cn
6
7

8 Hong Yan, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China. Fax
9
10 +86 29 82655104, email xjtu_yh.paper@aliyun.com
11
12
13
14

15 **Abstract**

16
17
18 **Objectives** This study aims to examine the prevalence and factors related to rational micronutrient
19
20 supplementations before and during pregnancy among women in Northwestern China, under the
21
22 background of lack of dietary intake in this region ¹.
23
24

25
26 **Design** A large-scale cross-sectional survey.
27

28
29 **Setting** Twenty counties and ten districts of Shaanxi Province.
30

31
32 **Participants** Total 28678 women (aged 16-49 years) who had live birth babies during 2010-2013
33
34 and who provided clear information about maternal micronutrient supplementations were selected by
35
36 using stratified multistage random sampling method in this study.
37
38

39
40 **Outcomes** The use of micronutrient supplements including folic acid (FA), iron, calcium, and
41
42 multiple micronutrients (MMN). Rational use of micronutrient supplements according to initiation
43
44 time and total days of use. Generalized estimating equation (GEE) models were performed to analyze
45
46 the factors associated with rational micronutrient supplementations.
47
48

49
50 **Results** In total, 83.9% of women took micronutrient supplements before or during their recent
51
52 pregnancy. FA (67.6%) and calcium (57.5%) were the primarily used micronutrient supplements, but
53
54 small parts of participants used MMN (14.0%) or iron (5.4%). The prevalence of rational uses were
55
56 very low for most micronutrients (7.4% for FA, 0.8% for iron, 3.2% for MMN and 23.2% for calcium).
57
58
59
60

1
2
3 Higher education and income levels, urban residents, as well as better antenatal cares including had
4
5 aristogenesis consultation and a higher frequency of antenatal visits were usually associated with the
6
7 increased rational micronutrient supplementations.
8
9

10 **Conclusion** Maternal micronutrient supplementations in Northwestern China were far from qualified
11
12 according to the Chinese guideline or WHO recommendation. Targeted health education and future
13
14 nutritional guidelines are suggested to improve rational maternal micronutrient supplementations,
15
16 especially for women with disadvantaged sociodemographic conditions.
17
18
19
20
21
22

23 **Keywords:** Micronutrient supplementation; Pregnancy; Prevalence; Initiation time of use; Total use
24
25 days; Associated-factors
26
27

28 **Running Head:** Rational maternal micronutrient supplementations
29

30 **Word count:** 3756
31
32
33
34
35

36 **Strengths and limitations of this study**

37

- 38
39 • This is the first study that detailed describing the situation of rational maternal micronutrient
40
41 supplementations in Northwestern China, which could serve as a data basis for developing health
42
43 education strategies in the future.
44
45
- 46
47 • Sample representativeness in Northwestern China is guaranteed by a large sample of 28678
48
49 women that recruited using a stratified multistage random sampling method
50
51
- 52
53 • The recall bias is ineluctable owing to the retrospective and self-reported information.
54
55
- 56
57 • The study does not provide an insight into the dosage of specific micronutrient supplementations
58
59 due to the uncertain specifications of some supplements.
60

- The generalisability of our findings to other geographical areas may be limited.

Introduction

Pregnancy is a process that involves the increasing of macro- and micronutrients requirement induced by maternal physiological changes and fetal growth². During pregnancy, adequate micronutrient intake is hard to achieve just from the daily diet³, and maternal micronutrient deficiencies could cause severe adverse outcomes including stillbirth, low birth weight and birth defects⁴. Maternal micronutrient supplementation is an alternative in addition to the adjustment of diet pattern and quality to fulfill the increased nutrition demands during pregnancy⁵. Growing evidence showed that supplementation of certain micronutrients during pregnancy could improve maternal health status as well as birth outcomes⁶⁻⁹. Routine micronutrient supplementations were recommended in developed countries as well as by WHO. Many developed countries implemented folic acid (FA) supplementation before and during the first trimester for protecting against neural tube defects (NTDs)^{10,11}. Additionally, WHO provide targeted recommendations of micronutrient supplementations, such as FA, iron, and calcium, for diverse populations to reduce the risk of adverse pregnancy outcomes^{12,13}. However, adherence to these recommendations varied from countries^{3,5,14}.

In China, National Health Commission (NHC) promotes the nutritional intervention that supplementation of FA (400 µg) daily during the periconceptional period to prevent congenital NTDs, especially for women in rural areas^{15,16}. In addition, Chinese nutrition society recommends women who preparing for pregnancy or being pregnant to take daily FA supplement during the time from 3-

1
2
3 months before pregnancy to the time at delivery for the prevention of NTDs and pregnancy-induced
4
5 hypertension ¹⁷. There are no more guidelines to direct other micronutrient supplementations so that
6
7 the use of micronutrient supplements during pregnancy varied in geographic areas and socioeconomic
8
9 groups. Previous studies reported that 81.8% of women in Sichuan Province of China consumed
10
11 micronutrient supplements during pregnancy and calcium (63.9%) were the most popular to use
12
13 among the participants ⁵. In addition, the result of a cross-sectional research showed that the overall
14
15 prevalence of micronutrient supplementations among pregnant women in urban and rural areas were
16
17 81.8% and 57.8%, respectively, along with the consumption of specific micronutrients in urban were
18
19 all significantly higher than that in rural ¹⁸.

20
21
22
23
24
25
26 To ensure the effectiveness of micronutrient supplementations for prevention of adverse pregnancy
27
28 outcomes, health policies or recommendations on the topic of micronutrient supplementations all
29
30 emphasized the timing and sustainability of use. For instance, daily use during the periconceptional
31
32 period is recommended for FA supplementation in preventing NTDs. Additionally, daily iron and
33
34 folic acid supplementation are recommended as part of the antenatal care to reduce the risk of low
35
36 birth weight, maternal anemia, and iron deficiency. Evidence showed that low compliance that
37
38 determined according to timing and days of use was a major reason for the low effectiveness of
39
40 micronutrient supplementations ^{9,19}, which indicated the importance of rational use of micronutrient
41
42 supplements rather than merely using. However, few of the previous studies focused on the rationality
43
44 of maternal micronutrient supplementation.

45
46
47
48
49
50
51
52 Shaanxi Province is a developing area in Northwestern China and can be geographically divided into
53
54 3 regions, which are northern, central and southern Shaanxi. The climate, culture and economic
55
56 development of these three regions vary significantly, as well as the diet habit of residents ¹.

1
2
3 According to previous researches in this region, most of the micronutrients taken from the diet were
4
5 inadequate among pregnant women ^{1,20}, and therefore, micronutrient supplementation seems to be
6
7 very pivotal for improving the health status of both mothers and infants. However, data about the
8
9 maternal micronutrient supplementation is still not available, especially lack of information on the
10
11 rational use of supplements. This article investigates the condition of maternal micronutrient
12
13 supplementations in Shaanxi, focuses on analyzing the prevalence and associated-factors of rational
14
15 supplement use, and aims to provide evidence for future evaluation of health policy effectiveness and
16
17 development of health education strategies.
18
19
20
21
22
23
24
25

26 **Methods**

27 **Data source and participants**

28
29 The study employed data from a large-scale cross-sectional survey, which was conducted between
30
31 August to November 2013 in Shaanxi province with the purpose of investigating the prevalence and
32
33 risk factors of birth defects among newborns, along with the maternal dietary condition and nutritional
34
35 supplements use. The target population were women aged from 16 to 49 years, pregnant during 2010-
36
37 2013 and had specific pregnant outcomes before the survey. The sample of the study was acquired
38
39 from twenty counties and ten districts of Shaanxi with applying a stratified multistage random
40
41 sampling method ^{1,21}. Twenty counties and ten districts were randomly selected firstly from the eighty
42
43 rural counties and twenty-four urban districts in Shaanxi Province according to the difference in size,
44
45 distribution and fertility rates of population between rural and urban areas. Subsequently, in the rural
46
47 area, six townships were randomly obtained from each chosen county, and then six villages were
48
49 randomly selected from each sampled township. Finally, thirty eligible women were randomly
50
51
52
53
54
55
56
57
58
59
60

1
2
3 selected in each village. In the urban area, three streets were randomly selected from each sampled
4
5 district, six communities were randomly chosen from each selected street, and then sixty eligible
6
7 women were selected in each community. Data collection was completed with a structured-
8
9 questionnaire via face-to-face survey by trained interviewers. Information including maternal
10
11 sociodemographic characteristics, lifestyle, health condition, health care utilization, and supplements
12
13 consumption, etc. were collected. Strict quality control process was utilized to guarantee data integrity
14
15 and accuracy ¹.
16
17
18
19

20
21 A total sample of 30027 women were enrolled in the survey after excluding women with limited
22
23 cognitive capacity or without informed consent. In order to obtain more accurate analysis results, the
24
25 present study only regarded women who had live birth babies in the recent pregnancy and who
26
27 provided clear information about maternal nutritional supplements use as eligible participants. Total
28
29 28678 women were chosen for the final analysis. **(Figure 1)**
30
31
32
33
34
35

36 **Maternal sociodemographic characteristics, birth history, and antenatal care information**

37
38
39 Maternal characteristics were collected according to the unified questionnaire. Maternal age at
40
41 delivery was divided into three categories (<25, 25-34 and ≥35years), as well as education level
42
43 (Junior high school or below, senior high school and college or above), geographic area (Southern
44
45 Shaanxi, Central Shaanxi and Northern Shaanxi) and per capita annual household income (Low:
46
47 <8800, Medium: 8800-15200 and High: ≥15200 Yuan, where 1 Yuan=0.144 \$US on 26 Nov 2018).
48
49
50 Residence (urban and rural) and parity (primiparous and multiparous) were classified into two
51
52 categories. antenatal care information including the number of antenatal visits (<5 and ≥5), the type
53
54 of hospitals for antenatal visit (hospitals below the county level and county level hospitals or above)
55
56
57
58
59
60

1
2
3 and aristogenesis consultation (yes and no, referred to the participation of health counseling that
4
5 related to maternal health care and fetal development before or during pregnancy) were investigated.
6
7
8
9

10 **Micronutrient supplementations**

11
12
13 Information about the use of micronutrient supplements in forms of tablet and capsule were mainly
14
15 collected, including folic acid (FA), iron, multiple-micronutrients that contain FA and iron (MMN),
16
17 calcium, vitamin C, B vitamins and others. Women who consumed any micronutrient supplement
18
19 before or during their recent pregnancy were considered as micronutrient supplement users, otherwise,
20
21 were considered as non-users.
22
23
24
25

26 The timing of supplementation we focused was from 3-month before the last menstrual period to the
27
28 time at delivery. 3-month before the last menstrual period was defined as the preconceptional period;
29
30 the time through the preconceptional period to the first trimester was defined as the periconceptional
31
32 period; the time of the second and third trimester was defined as the after-periconceptional period.
33
34
35

36 Rational micronutrient supplementations were evaluated according to Chinese guideline and WHO
37
38 recommendation as mentioned in the introduction section. The initiation time and total days of use
39
40 were the two factors that determined the classification of rational use. In the present study, initiated
41
42 from the periconceptional period with longer than 180 days of use was considered as rational use of
43
44 FA, otherwise, was irrational use. Similarly, initiated from the periconceptional period with longer
45
46 than 90 days of use was considered as rational use of iron, and the same to MMN. For calcium,
47
48 rational use was defined as supplementation before or during pregnancy with total days of use longer
49
50 than 90.
51
52
53
54
55
56
57
58
59
60

Statistical analysis

Dataset was established using Epidata 3.1 (The Epidata Association, Odense, Denmark) with double entry. Multiple imputation was used to attribute values for the missing variables including income level (n=5830), maternal age group (n=434), and the type of hospitals for antenatal visits (n=327), taking education level, geographic area, residence, parity, the number of antenatal visits and aristogenesis consultation as covariates with 5 imputed data sets²². Percentages (%) were estimated for reporting categorical variables, as well as for examining the prevalence of micronutrient supplements use among different groups. Comparisons between groups were completed by the Chi-square test. Prevalence of main supplements use according to initiation time and total days of use were exhibited with percentage stacked column chart using Microsoft Excel software version 2016. Because of the hierarchical structure of the data derived from the stratified multistage random sampling design, GEE models²³ with random effect at county level were applied to estimate adjusted odds ratio (OR) and 95% confidence interval (CI) for rational use of main micronutrient supplementations. Maternal characteristics including age, education, residence, income, parity, aristogenesis consultation, the number of antenatal visit and type of hospitals for antenatal visits were the fixed effects in the GEE models. Rational use of main micronutrient supplementations were binary outcomes so that binomial distribution and logit link function were used in the GEE analysis. An exchangeable covariance structure was used for all GEE models. Model 1 analyzed the relationship between rational use of main micronutrient supplementations and the sociodemographic characteristics including age, education, residence and income. Model 2 analyzed the relationship between rational use of main micronutrient supplementations and sociodemographic characteristics (all the variables in model 1) as well as parity, and antenatal care characteristics. The criteria for

1
2
3 statistical significance was $P < 0.05$. All analysis were performed using SAS version 9.4 (SAS
4
5 Institute, Cary, NC, USA).
6
7
8
9

10 **Result**

11 **Maternal characteristics according to micronutrient supplementations among participants**

12
13
14
15 There were significant differences in the aspects of the maternal sociodemographic condition, birth
16 history and antenatal care characteristics between users and non-users of micronutrient supplements
17
18 (**Table 1**). Users of micronutrient supplements were more likely aged between 25-34 years at delivery,
19 with higher education and income level, from central Shaanxi and lived in rural area, as well as
20
21 primiparous and had better antenatal care including took part in aristogenesis consultations, chose
22
23 higher-level hospitals, and had a higher frequency of antenatal visits.
24
25
26
27
28
29
30
31
32
33

34 **Prevalence of overall and rational micronutrient supplementations among participants**

35
36 In total, 83.9% of women took at least one micronutrient supplement during their last pregnancy. The
37 main supplements used by participants were folic acid (FA) (67.6%), calcium (57.5%), MMN
38 (14.0%), and iron (5.4%) (**Table 2**). Most of micronutrient supplements users did not reach the
39 rational use requirements according to the total days and timing of use. Although FA had a relatively
40
41 higher prevalence of use during the periconceptual period (64.5%), only 7.4% of women adhered
42
43 to used FA for longer than 180 days. Compare to the prevalence that who begin to use iron, MMN or
44
45 calcium in the after-periconceptual period (3.7% for iron, 8.2% for MMN and 39.0% for calcium),
46
47 smaller proportion of women commence to take them during periconceptual period (1.7% for iron,
48
49 5.8% for MMN and 18.5% for calcium). Additional, few of the participants who used iron, MMN or
50
51
52
53
54
55
56
57
58
59
60

1
2
3 calcium met the rational use requirements (0.8% for iron, 3.2% for MMN and 23.2% for calcium).
4
5 **(Table 3 and Figure 2)**. Because that MMN contains FA and iron ingredients, we further examined
6
7 the rational supplementation of FA and iron by combining the use of FA or iron with MMN. Still, the
8
9 prevalence of rational supplementation of FA and iron were low (8.5% for FA, 3.8% for iron, not
10
11 shown in table).
12
13
14
15
16
17

18 **Factors associated with rational micronutrient supplementations among participants**

19
20 **Table 4** showed the results of GEE analysis. Higher education and income levels, urban residents, as
21
22 well as better antenatal care including had aristogenesis consultation and a higher frequency of
23
24 antenatal visits were usually associated with the increased rational micronutrient supplementations.
25
26 Multipara were less likely to use micronutrient supplements rationally. Moreover, women aged in 25-
27
28 34 were more likely to increase the probability of rational use of FA, but elder than 35 was associated
29
30 with decreased probability of rational use of calcium. The type of hospitals for antenatal visits was
31
32 not related with rational micronutrient supplementations.
33
34
35
36
37
38
39
40

41 **Discussion**

42
43 Maternal micronutrient supplementations is a common way to compensate for the insufficient
44
45 nutrition intake from daily diet, which could contribute to healthy pregnancy outcomes as indicated
46
47 in many studies. The present study reports the maternal micronutrient supplementations among
48
49 pregnant women in Northwestern China, and focuses to examine the prevalence and associated-
50
51 factors of rational micronutrient supplementations according to initiation time and total days of use.
52
53
54
55 The results reveals two main problems of maternal micronutrient supplementations among our
56
57
58
59
60

1
2
3 population. On the one hand, the prevalence of micronutrient supplementations was lower than
4
5 expected. On the other hand, the micronutrient supplementations among our population, particularly
6
7 in the sociodemographic-disadvantageous groups, were far from rational according to Chinese
8
9 guideline and WHO recommendations.

10
11
12
13 Totally, the prevalence of maternal micronutrient supplementations in Shaanxi during 2010-2013 was
14
15 83.9%. Compared with other countries, our prevalence was higher than that of United States in 1999-
16
17 2006 (77.6%)³ but lower than those of Sydney, Australia in 2014 (93.8%)²⁴, Seoul, Korea in 2012
18
19 (88%)²⁵. Compared with the domestic data, it was similar to that of Sichuan Province (81.8%) in
20
21 2010⁵ and higher than the overall prevalence of eight Provinces of China in 2009 (66.4%)¹⁸. FA,
22
23 calcium, MMN, and iron were the four supplements primarily used by participants. Maternal FA
24
25 supplementation is associated with the prevention of NTDs as well as the reduced risk of preterm
26
27 delivery and small for gestational age (SGA) births²⁶. Both WHO and CNS developed guidelines for
28
29 promoting daily FA supplementation before and during pregnancy^{12,17}. In our population, among all
30
31 kinds of investigated micronutrient supplements, FA was the most popular one used before and during
32
33 pregnancy, but there were still over than 30% of women did not take FA during their recent pregnancy.
34
35 Additionally, the NHC of China recommends FA supplementation at least during the six months of
36
37 the periconceptual period¹⁶, but only a small part of women took FA supplement for preparing for
38
39 pregnancy, most of the women start to take FA supplement after they were pregnant. In addition, the
40
41 more serious reality is merely 7.4% of women rationally use FA supplement initiated from the
42
43 periconceptual period with longer than 180 total days of use. Even though considering the
44
45 contribution of MMN use to the total prevalence of rational FA supplementation, less than 10% of
46
47 women achieved the requirement. Because of the low intake of dietary folate (249 μg) among
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 pregnant women in this region ¹, qualified timing and continuity of use are essential for the
4
5 effectiveness of FA supplementation in the aspect of preventing adverse birth outcomes.
6

7
8 Pregnant anemia in China is a moderate or severe public health problem due to its high prevalence
9
10 among women ²⁷. Iron deficiency (ID) is the most common cause of anemia ²⁸ and iron deficiency
11
12 anemia (IDA) was one of the most important factors contributing to increased morbidity and mortality
13
14 in pregnant women ²⁹. Reviews stated that daily or intermittent iron supplementation in pregnancy
15
16 could be effective in improving iron status and reduce the risk of maternal IDA, which finally
17
18 promotes birth outcomes ^{7,30,31}. Although daily maternal iron supplementation during pregnancy is
19
20 recommended by WHO for the prevention of adverse pregnancy outcomes ¹², our participants rarely
21
22 used iron supplement before or during pregnancy. What was worse, unreasonable supplementations
23
24 of iron exist in our population as well. Previous studies demonstrated that prophylactic iron
25
26 supplementation from early in pregnancy benefited for improving birth weight, iron status and
27
28 reducing preterm birth ^{30,32}. Nevertheless, among our participants, many users took iron after the
29
30 periconceptional period, and few women insisted on taking it longer than 90 days. This may indicate
31
32 that most women took iron for curing ID or IDA during the second half of pregnancy, but the
33
34 prophylactic supplementation was very rare. When taking the use of both iron and iron-containing
35
36 MMN into consideration, the prevalence of rational iron supplementation was still very low (3.8 %).
37
38 This situation possibly attributed to the lack of maternal iron supplementation guideline in China and
39
40 the popular use of antianemic Chinese patent medicines in this region ³³.
41
42
43
44
45
46
47
48
49
50

51
52 The evidence demonstrated that periconceptional MMN supplementation with iron and folic acid
53
54 could promote iron status and some birth outcomes in term of reducing the risk of LBW, SGA and
55
56 congenital abnormalities ³⁴⁻³⁷. Meanwhile, besides the effects on pregnancy outcomes,
57
58
59
60

1
2
3 periconceptional MMN supplementation with adequate total dose was associated with the long-term
4
5 intellectual development of offspring ³⁸. The developed country like Australia had a high prevalence
6
7 of periconceptional MMN intake (79.2%) ²⁴. However, the prevalence of MMN supplementation
8
9 among our participants was only 14.0%, and merely 5.6% of women met its rational use requirement.
10
11 Consideration of situations including high incidence of adverse birth outcomes ³⁹, low intakes of most
12
13 micronutrients from daily diet ¹ and disadvantageous-sociodemographic conditions among many
14
15 pregnant women, the suggestion that to replace iron and folic acid with MMN supplement for
16
17 pregnant women in low-income areas ³⁵ might be an useful strategy to comprehensively improve
18
19 maternal micronutrient supplementations in this region.

20
21 For calcium supplementation, WHO recommends that in populations with low dietary calcium intake,
22
23 pregnant women should take daily oral calcium supplementation (1.5 g - 2.0 g) to reduce the risk of
24
25 pre-eclampsia and further to prevent maternal deaths and preterm births ¹³. In our population, daily
26
27 intake of calcium from diet among pregnant women (512 mg) was lower than the recommended
28
29 nutrient intakes (RNI) based on *Chinese Dietary Reference Intakes 2013* ¹, however, more than 40%
30
31 of women did not take calcium supplements during their last pregnancy. Moreover, less than a quarter
32
33 of participants supplement with calcium rationally without consideration of initiation time and the
34
35 dose of use, which suggested that there is still a gap between the situation of calcium supplementation
36
37 and the WHO recommendation.

38
39 When examining the population distribution of rational micronutrient supplementations, we found
40
41 that better sociodemographic conditions including urban residence, higher education and income
42
43 levels, along with better antenatal care in aspects of taking aristogenesis consultation and higher
44
45 frequency of antenatal visits were associated with increased prevalence of rational micronutrient
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 supplementations. Although the relationship between education level, prenatal health counseling and
4
5 the micronutrient supplementations were demonstrated in researches of the developed country like
6
7 Finland ⁴⁰ or of the domestic region like Sichuan ⁵, few studies reported the information of rational
8
9 micronutrient supplementations. Our finding of higher age and primiparity were the predictors of
10
11 rational use of FA was consistent with the previous report in Ireland ⁴¹. We did not find the difference
12
13 of rational FA supplementation between women who took antenatal visits in higher-level hospitals
14
15 and in township hospitals. This may reflect the balanced implement of national health policy on
16
17 maternal FA supplementation in the health system of the study region.
18
19
20
21
22

23 To our knowledge, this is the first study investigated the maternal micronutrient supplementations in
24
25 Northwestern China. Meanwhile, the prevalence and population distribution of rational micronutrient
26
27 supplementations were detailed analyzed according to initiation time and total days of use, which
28
29 could serve as a data basis for developing health education strategies in the future. In addition,
30
31 according to the proportion of rural to urban residents, population size and fertility rate in Shaanxi, a
32
33 large sample of 28678 women were recruited from twenty counties and ten districts of Shaanxi using
34
35 a stratified multistage random sampling method to guarantee its representativeness. Nonetheless,
36
37 several limitations of the present study should be stated. First, this study was retrospective and all the
38
39 information of micronutrient supplementations were self-reported from participants, and therefore the
40
41 recall bias were ineluctable. Second, the specifications of some supplements were uncertain, so that
42
43 the accurate dosage used by our participants could not be calculated. As a result, we only define
44
45 rational micronutrient supplementations according to initiation time and total days of use, without
46
47 consideration of dose of use. Third, the sources of recommendation regarding the use of supplements
48
49 were not recorded, hence, the approach that more proper for future interventions could not be known.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Finally, due to the diversities of economy, culture, lifestyle, as well as eating habits in different
4
5 geographical areas of China, the generalisability of our findings to other geographical areas may be
6
7 limited. Further quantitative analysis of the association between micronutrient supplementations and
8
9 pregnancy health and the investigation of the better way for health education are recommended to be
10
11 conducted in the future.
12
13
14
15
16
17

18 **Conclusion**

19
20 In conclusion, maternal micronutrient supplementations in Shaanxi failed to meet the Chinese
21
22 guideline or WHO recommendation according to initiation time and total days of use. Improving
23
24 rational micronutrient supplementations before or during pregnancy is still a burning issue for
25
26 maternal and child health in Northwestern China. Targeted health education and future guidelines of
27
28 micronutrient supplementations are suggested to be implemented, especially for women with
29
30 disadvantaged sociodemographic conditions.
31
32
33
34
35
36
37
38

39 **Acknowledgments**

40 The authors are grateful to all women who took part in this research, all staff who coordinated
41
42 fieldwork and all investigators who contributed to data collection.
43
44
45

46 **Ethics**

47
48 This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and
49
50 all procedures involving human subjects were approved by the Ethic Review Committee and
51
52 Academic Committee of Xi'an Jiaotong University Health Science Center (number 2012008).
53
54 Written informed consent was obtained from all participants.
55
56
57

58 **Funding**

1
2 This work was supported by the National Natural Science Foundation of China (grant number
3 81230016 and 81202218); and Shaanxi Health and Family Planning Commission (grant number
4 81230016 and 81202218); and Shaanxi Health and Family Planning Commission (grant number
5 81230016 and 81202218); and Shaanxi Health and Family Planning Commission (grant number
6 Sxwsjswzfcgght2016-013).
7
8
9

10 **Competing interests**

11 None.
12
13
14
15

16 **Contributors**

17 D.L., Y.C., L.Z., and H.Y. conceived and designed the study; D.L., S.L., F.L., B.M., R.Z., J.L.
18 collected and cleared the data; D.L., D.W., Y.Z., C.L., S.L., F.L., and P.Q. analyzed and interpreted
19 the data; D.L., Y.C., S.D., and L.Z. drafted and revised the manuscript. All authors read and approved
20 the data; D.L., Y.C., S.D., and L.Z. drafted and revised the manuscript. All authors read and approved
21 the final version of the manuscript.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Yang J, Dang S, Cheng Y, *et al.* Dietary intakes and dietary patterns among pregnant women in Northwest China. *Public Health Nutr.* 2017;**20**:282-293. doi: 10.1017/s1368980016002159.
2. Imdad A, Yakoob MY, Bhutta ZA. The effect of folic acid, protein energy and multiple micronutrient supplements in pregnancy on stillbirths. *BMC Public Health.* 2011;**11 Suppl 3**:S4. doi: 10.1186/1471-2458-11-s3-s4.
3. Branum AM, Bailey R, Singer BJ. Dietary supplement use and folate status during pregnancy in the United States. *J Nutr.* 2013;**143**:486-492. doi: 10.3945/jn.112.169987.
4. Gernand AD, Schulze KJ, Stewart CP, *et al.* Micronutrient deficiencies in pregnancy worldwide: health effects and prevention. *Nat Rev Endocrinol.* 2016;**12**:274-289. doi: 10.1038/nrendo.2016.37.
5. Tang L, Lee AH, Yau KKW, *et al.* Consumption of dietary supplements by Chinese women during pregnancy and postpartum: A prospective cohort study. *Matern Child Nutr.* 2017;**13**. doi: 10.1111/mcn.12435.
6. Hofmeyr GJ, Lawrie TA, Atallah AN, *et al.* Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev.* 2014:Cd001059. doi: 10.1002/14651858.CD001059.pub4.
7. Pena-Rosas JP, De-Regil LM, Garcia-Casal MN, *et al.* Daily oral iron supplementation during pregnancy. *Cochrane Database Syst Rev.* 2015:Cd004736. doi: 10.1002/14651858.CD004736.pub5.
8. De-Regil LM, Pena-Rosas JP, Fernandez-Gaxiola AC, *et al.* Effects and safety of periconceptional oral folate supplementation for preventing birth defects. *Cochrane Database Syst Rev.* 2015:Cd007950. doi: 10.1002/14651858.CD007950.pub3.
9. Li N, Li Z, Ye R, *et al.* Impact of Periconceptional Folic Acid Supplementation on Low Birth Weight and

- 1
2
3 Small-for-Gestational-Age Infants in China: A Large Prospective Cohort Study. *J Pediatr*.
4
5 2017;**187**:105-110. doi: 10.1016/j.jpeds.2017.04.060.
6
7
- 8 10. Bibbins-Domingo K, Grossman DC, Curry SJ, *et al*. Folic Acid Supplementation for the Prevention of
9
10 Neural Tube Defects: US Preventive Services Task Force Recommendation Statement. *Jama*.
11
12 2017;**317**:183-189. doi: 10.1001/jama.2016.19438.
13
14
- 15 11. Teixeira JA, Castro TG, Wall CR, *et al*. Determinants of folic acid supplement use outside national
16
17 recommendations for pregnant women: results from the Growing Up in New Zealand cohort study.
18
19 *Public Health Nutr*. 2018;1-10. doi: 10.1017/s1368980018000836.
20
21
22
- 23 12. WHO. Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women. Geneva: World
24
25 Health Organization; 2012.
26
27
- 28 13. WHO. Guideline: Calcium supplementation in pregnant women. Geneva: World Health Organization;
29
30 2013.
31
32
- 33 14. Forster DA, Wills G, Denning A, *et al*. The use of folic acid and other vitamins before and during
34
35 pregnancy in a group of women in Melbourne, Australia. *Midwifery*. 2009;**25**:134-146. doi:
36
37 10.1016/j.midw.2007.01.019.
38
39
- 40 15. Berry RJ, Li Z, Erickson JD, *et al*. Prevention of neural-tube defects with folic acid in China. China-
41
42 U.S. Collaborative Project for Neural Tube Defect Prevention. *N Engl J Med*. 1999;**341**:1485-1490.
43
44 doi: 10.1056/nejm199911113412001.
45
46
- 47 16. NHC of the People's Republic of China. Notifications on the issuance of "program of folic acid
48
49 supplementation for the prevention of neural tube defects".
50
51 <http://www.nhfpc.gov.cn/tigs/s9660/200906/facb102b5c5a471788f8b8a8eed09a31.shtml>. Published
52
53 2009. Accessed.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

17. Chinese Nutrition Society. *Chinese Dietary Guidelines*. Tibet people's Press; 2013;116-131.
18. Wang J, Zhao L, Piao J, *et al*. [Nutrition and health status of pregnant women in 8 provinces in China]. *Wei Sheng Yan Jiu*. 2011;**40**:201-203.
19. Taye B, Abeje G, Mekonen A. Factors associated with compliance of prenatal iron folate supplementation among women in Mecha district, Western Amhara: a cross-sectional study. *Pan Afr Med*. 2015;**20**:43. doi: 10.11604/pamj.2015.20.43.4894.
20. Cheng Y, Dibley MJ, Zhang X, *et al*. Assessment of dietary intake among pregnant women in a rural area of western China. *BMC Public Health*. 2009;**9**:222. doi: 10.1186/1471-2458-9-222.
21. Pei L, Kang Y, Cheng Y, *et al*. The Association of Maternal Lifestyle with Birth Defects in Shaanxi Province, Northwest China. *Plos One*. 2015;**10**. doi: 10.1371/journal.pone.0139452.
22. Sterne JA, White IR, Carlin JB, *et al*. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ*. 2009;**338**:b2393. doi: 10.1136/bmj.b2393.
23. Hubbard AE, Ahern J, Fleischer NL, *et al*. To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. *Epidemiology*. 2010;**21**:467-474. doi: 10.1097/EDE.0b013e3181caeb90.
24. Shand AW, Walls M, Chatterjee R, *et al*. Dietary vitamin, mineral and herbal supplement use: a cross-sectional survey of before and during pregnancy use in Sydney, Australia. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 2016;**56**:154-161. doi: 10.1111/ajo.12414.
25. Kim H, Jang W, Kim KN, *et al*. Comparison of dietary food and nutrient intakes by supplement use in pregnant and lactating women in Seoul. *Nutr Res Pract*. 2013;**7**:199-206. doi: 10.4162/nrp.2013.7.3.199.
26. Zhang Q, Wang Y, Xin X, *et al*. Effect of folic acid supplementation on preterm delivery and small for

- 1
2
3 gestational age births: A systematic review and meta-analysis. *Reprod Toxicol*. 2017;**67**:35-41. doi:
4
5 10.1016/j.reprotox.2016.11.012.
6
7
8 27. WHO. Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia. 2008:1-51.
9
10 28. Lopez A, Cacoub P, Macdougall IC, *et al*. Iron deficiency anaemia. *Lancet*. 2016;**387**:907-916. doi:
11
12 10.1016/s0140-6736(15)60865-0.
13
14
15 29. McLean E, Cogswell M, Egli I, *et al*. Worldwide prevalence of anaemia, WHO Vitamin and Mineral
16
17 Nutrition Information System, 1993-2005. *Public Health Nutr*. 2009;**12**:444-454. doi:
18
19 10.1017/s1368980008002401.
20
21
22
23 30. Haider BA, Olofin I, Wang M, *et al*. Anaemia, prenatal iron use, and risk of adverse pregnancy
24
25 outcomes: systematic review and meta-analysis. *BMJ*. 2013;**346**:f3443. doi: 10.1136/bmj.f3443.
26
27
28 31. Pena-Rosas JP, De-Regil LM, Gomez Malave H, *et al*. Intermittent oral iron supplementation during
29
30 pregnancy. *Cochrane Database Syst Rev*. 2015:Cd009997. doi: 10.1002/14651858.CD009997.pub2.
31
32
33 32. Siega-Riz AM, Hartzema AG, Turnbull C, *et al*. The effects of prophylactic iron given in prenatal
34
35 supplements on iron status and birth outcomes: a randomized controlled trial. *Am J Obstet Gynecol*.
36
37 2006;**194**:512-519. doi: 10.1016/j.ajog.2005.08.011.
38
39
40
41 33. Liu DM, Li JM, Qu PF, *et al*. [Prenatal supplementations of iron, iron-containing multimicronutrients
42
43 and antianemic Chinese patent medicines in women in Shaanxi province, 2010-2013]. *Zhonghua Liu*
44
45 *Xing Bing Xue Za Zhi*. 2017;**38**:1466-1470. doi: 10.3760/cma.j.issn.0254-6450.2017.11.005.
46
47
48
49 34. Czeizel AE. Periconceptional folic acid and multivitamin supplementation for the prevention of neural
50
51 tube defects and other congenital abnormalities. *Birth Defects Res A Clin Mol Teratol*. 2009;**85**:260-
52
53 268. doi: 10.1002/bdra.20563.
54
55
56
57 35. Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. *Cochrane*
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Database Syst Rev. 2017;**4**:Cd004905. doi: 10.1002/14651858.CD004905.pub5.

36. Nguyen PH, Young M, Gonzalez-Casanova I, *et al.* Impact of Preconception Micronutrient Supplementation on Anemia and Iron Status during Pregnancy and Postpartum: A Randomized Controlled Trial in Rural Vietnam. *PLoS One.* 2016;**11**:e0167416. doi: 10.1371/journal.pone.0167416.
37. Wang YF, Pei LJ, Song XM, *et al.* Impact of periconceptional multi-micronutrient supplementation on gestation: a population-based study. *Biomed Environ.* 2013;**26**:23-31. doi: 10.3967/0895-3988.2013.01.003.
38. Zhu Z, Cheng Y, Zeng L, *et al.* Association of Antenatal Micronutrient Supplementation With Adolescent Intellectual Development in Rural Western China: 14-Year Follow-up From a Randomized Clinical Trial. *JAMA Pediatr.* 2018;**172**:832-841. doi: 10.1001/jamapediatrics.2018.1401.
39. Wang LL, Bai RH, Liu Q, *et al.* [Epidemiological study on adverse pregnancy outcomes in Shaanxi province]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2016;**37**:1379-1382. doi: 10.3760/cma.j.issn.0254-6450.2016.10.013.
40. Arkkola T, Uusitalo U, Pietikainen M, *et al.* Dietary intake and use of dietary supplements in relation to demographic variables among pregnant Finnish women. *Br J Nutr.* 2006;**96**:913-920.
41. Cawley S, Mullaney L, McKeating A, *et al.* An analysis of folic acid supplementation in women presenting for antenatal care. *J Public Health.* 2016;**38**:122-129. doi: 10.1093/pubmed/fdv019.

1
2
3 **Figure legends**
4

5 **Figure 1** Flow diagram of sampling strategy with exclusion criteria
6

7
8 **Figure 2** Prevalence of main supplements use according to total days and initiation time of use
9

10 among Chinese women in Shaanxi, 2010-2013. FA, folic acid; MMN, multiple-micronutrients. For
11

12
13 FA, iron and MMN, the two classes from the right side represent the prevalence of rational use
14

15 (shown in red dashed box); for calcium, the three classes from the right side represent the
16

17 prevalence of rational use (shown in red dashed box).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Maternal characteristics according to micronutrient supplementations among Chinese women in Shaanxi, 2010-2013

Characteristics	Micronutrient supplementations				<i>P</i> ^a
	Yes (n=24051)		No (n=4627)		
	<i>n</i>	%	<i>n</i>	%	
Sociodemographic characteristics					
Age (years)					<0.001
<25	7843	32.6	1615	34.9	
25-34	14299	59.5	2465	53.3	
≥35	1909	7.9	547	11.8	
Education					<0.001
Junior high school or below	14113	58.7	3611	78.0	
Senior high school	5114	21.3	627	13.6	
College or above	4824	20.0	389	8.4	
Geographic area					<0.001
Southern Shaanxi	5099	21.2	776	16.8	
Central Shaanxi	13731	57.1	1725	37.3	
Northern Shaanxi	5221	21.7	2126	45.9	
Residence					<0.001
Rural	15846	65.9	3455	74.7	
Urban	8205	34.1	1172	25.3	
Per capita annual household income (RMB)					<0.001
Low	7990	33.2	1714	37.0	
Medium	7819	32.5	1604	34.7	
High	8242	34.3	1309	28.3	
Birth history and antenatal care information					
Parity					<0.001
Primiparous	14651	60.9	2152	46.5	
Multiparous	9400	39.1	2475	53.5	
Aristogenesis consultation ^b					<0.001
No	17404	72.4	3981	86.0	
Yes	6647	27.6	646	14.0	
The number of antenatal visit					<0.001
<5	6310	26.2	2298	49.7	
≥5	17741	73.8	2329	50.3	
Type of hospitals for antenatal visits					<0.001
Township hospitals	2783	11.6	622	13.4	
County hospitals or above	21268	88.4	4005	86.6	

^a *P* values for the differences among groups were derived from the χ^2 tests or Fisher's exact test.

^b Referred to the participation of health counselling that related to maternal healthcare and fetal development before or during pregnancy.

Table 2 Prevalence of maternal micronutrient supplementations among Chinese women in Shaanxi, 2010-2013

Micronutrient supplements	n	%
Folic acid	19352	67.6
Calcium	16414	57.5
Multi-micronutrients	4018	14.0
Iron	1547	5.4
Vitamin C	1147	4.0
B Vitamins	814	2.8
Vitamin E	173	0.6
Others ^a	1271	4.4

^a Including vitamin A, vitamin D and fish oil.

Table 3 Prevalence of main supplements use according to initiation time among Chinese women in Shaanxi, 2010-2013^a

Initiation time	FA^b (N=28629)	Iron (N=28644)	MMN^b (N=28628)	Calcium (N=28548)
Periconceptual period	18469 (64.5)	499 (1.7)	1665 (5.8)	5292 (18.5)
3 months before pregnancy	4966 (17.4)	79 (0.3)	212 (0.8)	272 (1.0)
First trimester	13503 (47.2)	420 (1.5)	1453 (5.1)	5020 (17.6)
After-periconceptual period	883 (3.1)	1048 (3.7)	2353 (8.2)	11122 (39.0)

^a N=28678. The number of missing values for supplementation of FA, iron, MMN and calcium were 49, 34, 50 and 130. Values are numbers and percentage, n(%).

^b FA, folic acid; MMN, multiple-micronutrients.

Table 4 Prevalence and adjusted OR (95%CI) of rational use of main micronutrient supplements among Chinese women in Shaanxi, 2010-2013^a

Characteristics	n	FA		Iron		MMN		Calcium	
		Rational use ^b (%)	Adjusted OR (95%CI)	Rational use ^c (%)	Adjusted OR (95%CI)	Rational use ^c (%)	Adjusted OR (95%CI)	Rational use ^d (%)	Adjusted OR (95%CI)
Sociodemographic characteristics (Model 1)^e									
Age (years)									
<25	9458	5.3	Ref	0.5	Ref	2.0	Ref	21.1	Ref
25-34	16764	8.7	1.30 (1.11, 1.52)*	0.9	1.34 (1.06, 1.69)*	3.8	1.31 (1.10, 1.55)*	24.9	1.08 (1.02, 1.15)*
≥35	2456	6.3	1.22 (0.98, 1.51)	0.7	1.41 (0.81, 2.48)	2.8	1.33 (1.67, 1.65)	18.7	0.80 (0.70, 0.92)*
Education									
Junior high school or below	17724	4.9	Ref	0.4	Ref	1.8	Ref	19.3	Ref
Senior high school	5741	7.3	1.38 (1.18, 1.61)*	1.1	2.01 (1.42, 2.86)*	3.1	1.49 (1.22, 1.82)*	26.7	1.30 (1.20, 1.40)*
College or above	5213	15.9	2.59 (2.21, 3.05)*	1.6	2.13 (1.43, 3.17)*	7.8	2.93 (2.36, 3.65)*	32.0	1.51 (1.39, 1.65)*
Residence									
Rural	19301	5.9	Ref	0.5	Ref	2.3	Ref	20.5	Ref
Urban	9377	10.4	1.72 (1.08, 2.72)*	1.4	1.98 (1.28, 3.08)*	4.9	1.56 (1.01, 2.43)*	28.4	1.30 (0.92, 1.83)
Per capita annual household income (RMB)									
Low	9689	5.0	Ref	0.5	Ref	2.0	Ref	20.9	Ref
Medium	9402	6.4	1.07 (0.94, 1.23)	0.6	1.05 (0.71, 1.57)	2.5	1.12 (0.91, 1.37)	22.3	1.07 (0.99, 1.15)
High	9538	10.7	1.27 (1.11, 1.45)*	1.3	1.41 (0.94, 2.11)	5.0	1.39 (1.11, 1.73)*	26.2	1.14 (1.05, 1.24)*
Birth history and antenatal care information (Model 2)^f									
Parity									
Primiparous	16803	9.2	Ref	0.9	Ref	3.9	Ref	25.3	Ref
Multiparous	11875	4.8	0.70 (0.58, 0.84)*	0.6	1.19 (0.85, 1.67)	2.1	0.86 (0.70, 1.05)	20.0	1.03 (0.97, 1.10)
Aristogenesis consultation									
No	21385	5.6	Ref	0.6	Ref	2.6	Ref	20.7	Ref
Yes	7293	12.6	1.91 (1.71, 2.14)*	1.2	1.47 (1.28, 1.69)*	4.7	1.41 (1.22, 1.63)*	30.2	1.33 (1.22, 1.44)*
The number of antenatal visit									

1										
2	<5	8608	3.8	Ref	0.4	Ref	1.8	Ref	15.4	Ref
3										
4	≥5	20070	8.9	1.59 (1.35, 1.87)*	0.9	1.36 (1.13, 1.64)*	3.7	1.26 (1.04, 1.53)*	26.4	1.32 (1.22, 1.44)*
5	Type of hospitals for antenatal visits									
6	Township hospitals	3405	5.9	Ref	0.7	Ref	1.9	Ref	19.3	Ref
7										
8	County hospitals or above	25273	7.6	0.88 (0.73, 1.06)	0.8	0.81 (0.53, 1.24)	3.3	1.15 (0.93, 1.43)	23.6	1.11 (0.99, 1.23)

9 ^aN=28678. FA, folic acid; MMN, multiple-micronutrients. The number of missing values for supplementation of FA, iron, MMN and calcium were 49, 34, 50 and 130.

10 Adjusted OR and 95% CI were derived from GEE models with random effects at county level.

11 ^bRational use of FA was defined as that supplementation of FA initiated from periconceptional period with total days of use longer than 180, otherwise, defined as
12 irrational.

13 ^cRational use of iron/MMN was defined as that supplementation of iron/MMN initiated from periconceptional period with total days of use longer than 90, otherwise,
14 defined as irrational.

15 ^dRational use of calcium was defined as supplementation of calcium before or during pregnancy with total days of use longer than 90, otherwise, defined as irrational.

16 ^eModel 1 adjusted for the sociodemographic characteristics including maternal age, education, residence and income, and the OR and 95% CI of these characteristics
17 was derived from model 1.

18 ^fModel 2 adjusted for all variables in model 1 plus parity and antenatal care characteristics, and the OR and 95% CI of parity and antenatal care characteristics was
19 derived from model 2.

20 * Refers to P-value <0.05.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46




Figure 1 Flow diagram of sampling strategy with exclusion criteria

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46




Figure 2 Prevalence of main supplements uses according to total days and initiation time of use among Chinese women in Shaanxi, 2010-2013. FA, folic acid; MMN, multiple-micronutrients. For FA, iron, and MMN, the two classes from the right side represent the prevalence of rational use (shown in red dashed box); for calcium, the three classes from the right side represent the prevalence of rational use (shown in red dashed box).

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5-6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	None
		(c) Explain how missing data were addressed	9
		(d) If applicable, describe analytical methods taking account of sampling strategy	9
		(e) Describe any sensitivity analyses	None
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 1
		(b) Give reasons for non-participation at each stage	Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 3-4
Outcome data	15*	Report numbers of outcome events or summary measures	Table 1-4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 4
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	None
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	None
Discussion			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15-16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16-17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Low adherence to maternal micronutrient supplementation is still a burning issue for public health: based on a large-scale cross-sectional survey of Northwestern China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028843.R1
Article Type:	Research
Date Submitted by the Author:	19-Mar-2019
Complete List of Authors:	<p>Liu, Danmeng; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Cheng, Yue; Xi'an Jiaotong University Health Science Center, Department of Nutrition Dang, Shaonong; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Wang, Duolao; Liverpool University, Liverpool School of Tropical Medicine Zhao, Yaling; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Li, Chao; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Li, Shanshan; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Lei, Fangliang; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Qu, Pengfei; Northwest women's and children's Hospital, Translational Medicine Center Mi, Baibing; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Zhang, Ruo; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Li, Jiamei; Department of Emergency Medicine, the Second Affiliated Hospital, Xi'an Jiaotong University, Department of Emergency Medicine Zeng, L; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Yan, H; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics; Nutrition and Food Safety Engineering Research Center of Shaanxi Province</p>
Primary Subject Heading:	Public health
Secondary Subject Heading:	Public health, Nutrition and metabolism
Keywords:	Micronutrient supplementation, Pregnancy, Adherence, Associated-factors

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Low adherence to maternal micronutrient supplementation is still a burning issue for public**
4
5 **health: based on a large-scale cross-sectional survey of Northwestern China**
6
7
8
9

10 Danmeng Liu¹, Yue Cheng², Shaonong Dang¹, Duolao Wang³, Yaling Zhao¹, Chao Li¹, Shanshan
11
12 Li¹, Fangliang Lei¹, Pengfei Qu⁴, Baibing Mi¹, Ruo Zhang¹, Jiamei Li⁵, Lingxia Zeng¹*, Hong Yan¹

13
14
15 6 7 *

16
17
18
19
20
21 ¹Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong
22
23 University Health Science Center, No. 76 Yanta West Road, Xi'an, Shaanxi, 710061, China

24
25
26 ²Department of Nutrition, School of Public Health, Xi'an Jiaotong University Health Science Center,
27
28 No. 76 Yanta West Road, Xi'an, Shaanxi, 710061, China

29
30
31 ³Liverpool School of Tropical Medicine, Liverpool University, Pembroke Place, Liverpool, L3 5QA,
32
33 UK

34
35
36 ⁴Translational Medicine Center, Northwest women's and children's Hospital, No. 1616 Yanxiang
37
38 Road, Xi'an, Shaanxi, 710061, China

39
40
41 ⁵Department of Emergency Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University,
42
43 No. 157 West Fifth Road, Xi'an, Shaanxi, 710004, China

44
45
46
47 ⁶Nutrition and Food Safety Engineering Research Center of Shaanxi Province, Xi'an, Shaanxi,
48
49 710061, China

50
51
52 ⁷Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry
53
54 of Education, Xi'an, Shaanxi, 710061, China

55
56
57 *Corresponding author:
58
59
60

Lingxia Zeng, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China. Fax
+86 29 82655104, email tjzlx@mail.xjtu.edu.cn

Hong Yan, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China. Fax
+86 29 82655104, email xjtu_yh.paper@aliyun.com

Abstract

Objectives This study aims to report the situation of maternal micronutrient supplementation before and during pregnancy, and examine the rates of and factors related to the adherence to micronutrient supplementation in Northwestern China where dietary micronutrients deficiency is common.

Design A large-scale population-based cross-sectional survey.

Setting Twenty counties and ten districts of Shaanxi Province.

Participants Total 28678 women (aged 16-49 years) who provided clear information about maternal micronutrient supplementation were selected by using stratified multistage random sampling method in this study.

Main outcome measures The adherence to micronutrient supplements (including folic acid, iron, calcium, and multiple-micronutrients) are the outcomes. Factors associated with the adherence to micronutrient supplementation are analyzed using Generalized Estimating Equation (GEE) models.

Results In total, 83.9% of women took micronutrient supplements before or during pregnancy. FA (67.6%) and calcium (57.5%) were the primarily used micronutrient supplements, but small parts of participants used MMN (14.0%) or iron (5.4%). The adherence was low to all micronutrient supplementation (7.4% for FA, 0.8% for iron, 23.2% for calcium and 3.2% for MMN) according to the Chinese guideline (for FA) and WHO recommendations (for iron, calcium, and MMN). Higher

1
2
3 education and income levels, urban residents, as well as better antenatal cares including had
4
5 pregnancy consultation and a higher frequency of antenatal visits were usually associated with the
6
7 high adherence to micronutrient supplementation.
8
9

10 **Conclusion** Maternal micronutrient supplementation in Northwestern China was far from qualified
11
12 according to the Chinese guideline or WHO recommendation. Targeted health education and future
13
14 nutritional guidelines are suggested to improve this situation, especially for women with
15
16 disadvantaged sociodemographic conditions.
17
18
19

20
21
22
23 **Keywords:** Micronutrient supplementation; Pregnancy; Adherence; Associated-factors
24

25
26 **Running Head:** Adherence to maternal micronutrient supplementation
27

28
29 **Word count:** 4128
30
31

32 33 34 **Strengths and limitations of this study**

- 35
36 • This is the first large-scale and representative study that detailed describing the adherence to
37
38 maternal micronutrient supplementation in Northwestern China, which could serve as a data basis
39
40 for developing health education strategies in the future.
41
42
- 43
44 • Sample representativeness in Northwestern China is guaranteed by a large sample of 28678
45
46 women that recruited using a stratified multistage random sampling method
47
48
- 49
50 • The recall bias is ineluctable owing to the retrospective and self-reported information.
51
- 52
53 • The study does not provide an insight into the dosage of specific micronutrient supplementation
54
55 due to the uncertain specifications of some reported supplements.
56
- 57
58 • The generalizability of our findings to other geographical areas may be limited.
59
60

Introduction

Pregnancy is a process that involves the increasing of macro- and micronutrients requirement induced by maternal physiological changes and fetal growth ¹. During pregnancy, adequate micronutrient intake is hard to achieve just from the daily diet ², and maternal micronutrient deficiencies could cause severe adverse outcomes, including stillbirth, low birth weight (LBW) and birth defects ³. Micronutrients supplementation is an alternative in addition to the adjustment of diet pattern and quality to fulfill the increased nutrition demands during pregnancy ⁴. In recent decades, maternal micronutrients supplementation during pregnancy attracts more and more attention as growing evidence showed that it has significant benefits in the improvement of maternal health status as well as birth outcomes ⁵⁻⁸.

As a result, some micronutrients which greatly contribute to maternal and fetal health is highly recommended for routine use as a part of antenatal care. Many countries implemented periconceptionally folic acid (FA) supplementation for protecting against neural tube defects (NTDs) ^{9,10}. WHO also provide several guidelines for micronutrient supplementation for pregnant women to reduce the risk of adverse pregnancy outcomes ¹¹. WHO recommends daily use of FA (400 µg) start at 2-month before the planned pregnancy until 12 weeks of pregnancy for the prevention of NTDs ¹², and daily oral folic acid combined with iron supplementation (400 µg FA and 30-60 mg iron) throughout pregnancy is recommended to reduce the risk of LBW, maternal anemia and iron deficiency ¹³. In addition, daily oral calcium supplementation (1.5-2.0 g) in the second half of pregnancy is recommended for pregnant women in the area of low dietary calcium intake, to reduce the risk of pre-eclampsia ¹⁴.

1
2
3 China is the most populated developing country with a considerable incidence of adverse pregnancy
4
5 outcomes, including maternal anemia ¹⁵, LBW ¹⁶, small gestational age ⁸, etc., but the implementation
6
7 of folic acid supplementation project (take daily FA (400 µg) initiate from 3-month before pregnancy
8
9 to the end of the first trimester) to prevent NTDs, especially in rural areas, is the only nutritional
10
11 intervention promoted by the National Health Commission (NHC) for pregnant women and women
12
13 planning to be pregnant ^{17,18}. Also, the only routine antenatal micronutrient supplementation
14
15 recommended by the Chinese Nutrition Society (CNS) for childbearing-aged women is daily use of
16
17 FA (400 µg) start at 3-month before the planned pregnancy until the end of pregnancy ¹⁹, which is
18
19 similar to the WHO recommendation. There are no more guidelines for routine supplementation of
20
21 other micronutrients, so that the use of micronutrient supplements during pregnancy varied in Chinese
22
23 geographic areas and socioeconomic groups ^{4,20}.

24
25
26 Health policies and recommendations of micronutrient supplementations all emphasized the timing,
27
28 dosage, sustainability of use, as well as the target population. Evidence showed that low compliance
29
30 was a major reason for the low effectiveness of micronutrient supplementation ^{8,21}, and thus the
31
32 exploration of the determinants of the adherence is important for guiding the appropriate use to
33
34 guarantee the efficacy. Many factors were reported in relation to the adherence to micronutrient
35
36 supplementation, including maternal age, education background, occupation, antenatal care, etc.
37
38
39 Previous studies reported the compliance of micronutrient supplementation in the Western countries
40
41 like the United States and Norway ^{22,23}, as well as in the Africa countries like Ethiopia and Kenya
42
43 ^{24,25}. Few of the studies focused on the adherence to maternal micronutrient supplementation in China.
44
45 Shaanxi Province is a developing area in Northwestern China where most of the micronutrients took
46
47 from the diet among pregnant women were lower than the Chinese recommended nutrient intake
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (RNI) ^{26,27}, especially the intake of folate and calcium ^{26,27}. Although the dietary iron intake was close
4
5 to the RNI for the first and second trimester, most iron from diet was the non-heme iron, which is not
6
7 efficiently absorbed and utilized by the human body ²⁸. Additionally, about 40% of the childbearing-
8
9 aged women in the region suffered anemia ²⁹, and the incidence of adverse birth outcomes, including
10
11 LBW and preterm birth, were high in this region ³⁰. Therefore, maternal micronutrient
12
13 supplementation seems to be a relatively inexpensive and low-risk method for compensating for
14
15 inadequate dietary intake and improving the health status of both mothers and infants. However,
16
17 representative data from large-scale study on the maternal micronutrient supplementation in this
18
19 region is not available.
20
21
22
23
24
25

26 Accordingly, this article aims to investigate the condition of maternal micronutrient supplementation
27
28 in Shaanxi, focuses on analyzing the rates of and associated-factors related to the adherence to
29
30 supplement use according to existing recommendations, and to provide evidence for future evaluation
31
32 of health policy effectiveness and development of health education strategies.
33
34
35
36
37
38

39 **Methods**

40 41 **Data source and participants**

42
43 The study employed data from a large-scale population-based cross-sectional survey, which was
44
45 conducted between August to November 2013 in Shaanxi province with the purpose of investigating
46
47 the prevalence and risk factors of birth defects among newborns, along with the maternal dietary
48
49 condition and nutritional supplements use. The target population were women aged from 16 to 49
50
51 years, pregnant during 2010-2013 and had specific pregnant outcomes before the survey. The sample
52
53 of the study was acquired from twenty counties and ten districts of Shaanxi with applying a stratified
54
55
56
57
58
59
60

1
2
3 multistage random sampling method ^{27,31}. Twenty counties and ten districts were randomly selected
4
5 firstly from the eighty rural counties and twenty-four urban districts in Shaanxi Province according
6
7 to the difference in size, distribution and fertility rates of population between rural and urban areas.
8
9
10 Subsequently, in the rural area, six townships were randomly obtained from each chosen county, and
11
12 then six villages were randomly selected from each sampled township. Finally, thirty eligible women
13
14 were randomly selected in each village. In the urban area, three streets were randomly selected from
15
16 each sampled district, six communities were randomly chosen from each selected street, and then
17
18 sixty eligible women were selected in each community. Data collection was completed with a
19
20 structured-questionnaire via face-to-face survey by trained interviewers. Information including
21
22 maternal sociodemographic characteristics, lifestyle, health condition, health care utilization, and
23
24 supplements consumption, etc. were collected. Strict quality control process was utilized to guarantee
25
26 data integrity and accuracy ²⁷.

27
28
29
30
31
32
33
34 A total sample of 30027 women were enrolled in the survey after signing the informed consent and
35
36 excluding women with limited cognitive capacity. In order to obtain more accurate analysis results,
37
38 we further excluded who did not provide clear information about maternal nutritional
39
40 supplementation (total 1349 women, among them, 761 women had no live birth babies in the recent
41
42 pregnancy and refused to provide detailed information). Total 28678 women were chosen for the final
43
44
45
46
47 analysis.

51 52 **Maternal sociodemographic characteristics, parity, and antenatal care information**

53
54 Maternal characteristics were collected according to the questionnaire. Maternal age at delivery was
55
56 divided into three categories (<25, 25-34 and ≥35years), as well as education level (Junior high
57
58
59
60

1
2
3 school or below, senior high school and college or above), geographic area (Southern Shaanxi,
4
5 Central Shaanxi and Northern Shaanxi) and per capita annual household income (Low: <8800,
6
7 Medium: 8800-15200 and High: ≥ 15200 Yuan, where 1 Yuan=0.149 \$US on 17 Mar 2019).
8
9
10 Residence (urban and rural) and parity (primiparous and multiparous) were classified into two
11
12 categories. Antenatal care information including the number of antenatal visits (<5 and ≥ 5), the type
13
14 of hospitals for antenatal visit (hospitals below the county level and county level hospitals or above)
15
16 and pregnancy consultation (yes and no, referred to the participation of health counseling that related
17
18 to maternal health care and fetal development before or during pregnancy) were investigated.
19
20
21
22
23
24
25

26 **Micronutrient supplementation**

27
28 Information about the micronutrient supplements in forms of tablet and capsule were mainly collected.
29
30 We asked the participants to choose the supplements they used during pregnancy from a list of the
31
32 brand of supplements that were commonly provided in the local hospital or pharmacy, and they
33
34 should further tell the brand and kind of supplement they consumed if it was not shown in the list.
35
36 We did not list iron-FA supplement in the questionnaire due to that few supplements on the market
37
38 are the two-nutrient formulation of iron and FA. In the analysis, FA supplements referred to those
39
40 contains only FA; iron supplements referred to those contains only iron; calcium supplements referred
41
42 to those contains only calcium or calcium plus another micronutrient (including calcium-vitamin D
43
44 and calcium-zinc); multiple-micronutrient (MMN) supplements referred to those contains FA, iron
45
46 and other micronutrients. Women who consumed any micronutrient supplement before or during their
47
48 recent pregnancy were considered as micronutrient supplement users, otherwise, were regarded as
49
50 non-users.
51
52
53
54
55
56
57
58
59
60

1
2
3 We further obtained the time and total days of use of each supplement they reported. The participants
4
5 were required to select the time of supplement use from the four pregnant periods (3-month before
6
7 the last menstrual period, the first trimester, the second trimester, and the third trimester) and report
8
9 the total days of supplementation for each supplement they used. 3-month before the last menstrual
10
11 period was defined as the preconceptional period; the time through the 3-month before the last
12
13 menstrual period to the end of first trimester was defined as the periconceptional period; the time of
14
15 the second and third trimester was defined as the after-periconceptional period.
16
17
18
19

20
21 Adherence to micronutrient supplementation was determined by the initiation time and total days of
22
23 use according to Chinese guideline (for FA) and WHO recommendations (for iron, calcium, and
24
25 MMN). Although WHO did not universally recommend MMN supplementation (MMS) for pregnant
26
27 women, due to its components of iron and FA, we still examine the compliance of MMS by
28
29 referencing the WHO recommendation for iron and FA supplementation. We applied total days of
30
31 use instead of the total amounts because most of our investigated supplements were taken one tablet
32
33 per day. In the present study, the thresholds used to define the adhered total days of use were 180
34
35 days for FA and 90 days for others. Therefore, adhered to FA supplementation was defined as initiated
36
37 from the periconceptional period with ≥ 180 days of use, otherwise, was regarded as non-adhered;
38
39 adhered to iron supplementation was considered as initiated from the first trimester with ≥ 90 days of
40
41 use, otherwise, was regarded as non-adhered. For calcium supplementation, 20 weeks of gestation is
42
43 the initiation time recommended by WHO. Because of we did not collect the specific weeks of
44
45 gestation of micronutrient supplementation, adhered to calcium supplementation was considered as
46
47 initiated from the second trimester with ≥ 90 days of use, otherwise, was regarded as non-adhered;
48
49 adhered to MMS was defined as initiated from the first trimester with ≥ 90 days of use, otherwise,
50
51
52
53
54
55
56
57
58
59
60

1
2
3 was considered as non-adhered.
4
5
6
7

8 **Statistical analysis**

9

10 Dataset was established using Epidata 3.1 (The Epidata Association, Odense, Denmark) with double
11 entry. Multiple imputation was used to attribute values for the missing variables, including income
12 level (n=5830), maternal age group (n=434), and the type of hospitals for antenatal visits (n=327),
13 taking education level, geographic area, residence, parity, the number of antenatal visits and
14 pregnancy consultation as covariates with 5 imputed data sets ³². Numbers and percentages (n (%))
15 were estimated for reporting the rate of micronutrient supplementation in different groups and for
16 presenting the adherence to micronutrient supplementation. Comparisons between groups were
17 completed by the Chi-square test or Fisher's exact test.
18
19
20
21
22
23
24
25
26
27
28
29

30
31 Because of the hierarchical structure of the data derived from the stratified multistage random
32 sampling design, we adopted two-level analysis to examine the relationship between maternal
33 characteristics and the adherence to micronutrient supplementation. Multivariable GEE models ³³
34 with random effect at county level were applied in the two-level analysis to estimate adjusted odds
35 ratio (OR) and 95% confidence interval (CI) for factors associated with the adherence to
36 micronutrient supplementation. Maternal characteristics including age, education, residence, income,
37 parity, pregnancy consultation, the number of antenatal visit and type of hospitals for antenatal visits
38 were the fixed effects in the GEE models. Adherence to supplementation of FA, iron, calcium, and
39 MMN were binary outcomes (adhered vs. non-adhered) so that binomial distribution and logit link
40 function were used in the GEE analysis. An exchangeable covariance structure was used for all GEE
41 models. Model 1 analyzed the relationship between the adherence to micronutrient supplementation
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 and the sociodemographic characteristics including age, education, residence and income. Model 2
3
4 analyzed the relationship between the adherence to micronutrient supplementation and
5
6 sociodemographic characteristics (all the variables in model 1) as well as parity, and antenatal care
7
8 characteristics. The criteria for statistical significance was $P < 0.05$. All analyses were performed
9
10
11 using SAS version 9.4 (SAS Institute, Cary, NC, USA).
12
13
14
15
16
17

18 **Patient and public involvement**

19
20 No patients were involved in developing the research question, outcome measure and design of the
21
22 study. We were unable to disseminate the results of the research directly to study participants, and
23
24 we informed the results to the local health authorities.
25
26
27
28
29
30

31 **Result**

32 **Maternal characteristics according to micronutrient supplementation**

33
34 There were significant differences in the aspects of the maternal sociodemographic condition, birth
35
36 history and antenatal care characteristics between users and non-users of micronutrient supplements
37
38 (**Table 1**). Users of micronutrient supplements were more likely aged between 25-34 years at delivery,
39
40 with higher education and income level, from central Shaanxi and lived in rural area, as well as
41
42 primiparous and had better antenatal care including took part in pregnancy consultations, chose
43
44 higher-level hospitals, and had a higher frequency of antenatal visits.
45
46
47
48
49
50
51
52
53
54

55 **Rates of and the adherence to micronutrient supplementation**

56
57 In total, 83.9% of women took at least one micronutrient supplement during their last pregnancy. The
58
59
60

1
2
3 main supplements used by participants were folic acid (FA) (67.6%), calcium (57.5%), MMN
4
5 (14.0%), and iron (5.4%) (**Table 2**). Although FA had a relatively higher rate of use during the
6
7 periconceptual period (64.5%), only 7.4% of women insisted to use it from periconceptual period
8
9 for longer than 180 days. Most of the users started to take calcium supplements during the second
10
11 trimester (39%), which is basically compliant to the recommended initiation time, but only 11.7%
12
13 met the recommendation after taking total days of use into consideration. Compare to the rate that
14
15 who began to use iron or MMN in the after-periconceptual period (3.7% for iron, and 8.2% for
16
17 MMN), smaller proportion of women commence to take them from the first trimester (1.7% for iron,
18
19 and 5.8% for MMN), and few of them adhered to use iron or MMN more than 90 days (0.6% for iron,
20
21 and 2.7% for MMN). (**Table 3**). We also found that very few women (0.2%) consumed FA plus iron
22
23 starting at the first trimester with more than 90 days of use (not shown in table). We further examined
24
25 the adherence to supplementation of FA, iron, and FA plus iron by taking the contribution of MMS
26
27 into consideration. Still, the rates of compliant use were low (8.5% for FA, 3.2% for iron, and 2.9%
28
29 for FA plus iron, not shown in table).
30
31
32
33
34
35
36
37
38
39
40
41

42 **Factors associated with the adherence to micronutrient supplementation**

43
44 Multivariable two-level analysis was used to identify factors related to the adherence to micronutrient
45
46 supplementation. **Table 4** shows the results of multivariable two-level analysis by GEE models.
47
48 Higher education and income levels, urban residents, as well as better antenatal care including had
49
50 pregnancy consultation and a higher frequency of antenatal visits were usually associated with the
51
52 adhered micronutrient supplementation. Women aged in 25-34 were more likely to adhere to the
53
54 supplementation of FA, iron, and MMN, but elder than 35 was associated with a lower probability of
55
56
57
58
59
60

1
2
3 adhered use of calcium. Multipara was less likely related to adhered FA supplementation. The type
4
5 of hospitals for antenatal visits was not linked to the adherence to micronutrient supplementation.
6
7
8
9

10 **Discussion**

11
12
13 In this large-scale cross-sectional study, we observed that micronutrient supplements were not used
14
15 as commonly as expected, and the adherence to micronutrient supplementation among our population,
16
17 particularly in women with sociodemographic-disadvantageous, were low based on the CNS and
18
19 WHO recommendations. Totally, the prevalence of maternal micronutrient supplementation in
20
21 Shaanxi during 2010-2013 was 83.9%. Compared with other countries, our overall use rate was higher
22
23 than that of United States in 1999-2006 (77.6%)² but lower than those of Sydney, Australia in 2014
24
25 (93.8%)³⁴, Seoul, Korea in 2012 (88%)³⁵. Compared with the domestic data, it was similar to that of
26
27 Sichuan Province (81.8%) in 2010⁴ and higher than the overall prevalence of eight Provinces of
28
29 China in 2009 (66.4%)²⁰. FA, calcium, MMN, and iron were the four supplements primarily used by
30
31 participants.
32
33
34
35
36
37
38

39 Maternal FA supplementation is associated with the prevention of NTDs as well as the reduced risk
40
41 of preterm delivery and small for gestational age (SGA) births³⁶. Both WHO and CNS developed
42
43 guidelines for promoting daily FA supplementation before and during pregnancy^{13,19}, and the
44
45 Chinese government also implemented the periconceptional FA supplementation to prevent NTDs
46
47 since 2009. In our population, FA was the most popular one used before and during pregnancy, but
48
49 there were still over than 30% of women did not take it. Additionally, most of the users start to take
50
51 FA supplement after they were pregnant, and only a small part took FA supplement for preparing for
52
53 pregnancy, which may indicate the high frequency of non-planning pregnancy or the lack of
54
55
56
57
58
59
60

1
2
3 knowledge about preconceptional FA supplementation. The more serious reality is merely 7.4% of
4
5 women adhered to FA supplementation periconceptionally with more than 180 days, and this rate still
6
7 less than 10% even considering the contribution of MMS. Therefore, the utilization of FA supplement
8
9 was failed to reach the recommendation among pregnant women in Northwestern China although
10
11 maternal routine folic acid supplementation is strongly promoted in China.
12
13

14
15 China has a high prevalence of pregnant anemia which is commonly caused by iron deficiency during
16
17 pregnancy ^{15,37}. Reviews stated that daily iron supplementation in pregnancy could be useful in
18
19 improving iron status and birth outcomes ^{6,38}. Only 5.4% of the participants consumed iron
20
21 supplement during pregnancy, and the low rate of iron supplementation possibly attribute to the lack
22
23 of routine maternal iron supplementation guideline in China and the popular use of antianemic
24
25 Chinese patent medicines among pregnant women in this region ³⁹. The proportion of women who
26
27 had compliant iron supplementation was very low in our population (0.6% for iron, 3.2% for iron and
28
29 iron-containing MMS), which is much lower than that (20.4% for FA-iron) of Western Amhara of
30
31 Ethiopia ²¹. On the basis of the WHO recommendation, maternal iron supplementation should be
32
33 started as early as possible during pregnancy ¹³, Our participants usually began to use iron supplement
34
35 after the periconceptional period rather than from the beginning of pregnancy. The reason for it may
36
37 be that most women only took iron supplement under the direction of physicians after the occurrence
38
39 of ID or IDA during the second half of pregnancy, but the prophylactic supplementation was very
40
41 rare.
42
43
44
45
46
47
48
49
50

51 Maternal calcium supplementation has a clear beneficial effect on hypertension-related disorders
52
53 during pregnancy and is possibly related to the reduction of preterm birth risk ⁴⁰. To prevent pre-
54
55 eclampsia, WHO recommends daily calcium supplementation from 20 weeks of gestation for
56
57
58
59
60

1
2
3 populations with low dietary calcium intake ¹⁴. Under the background of the low dietary calcium
4
5 intake among pregnant women (512 mg/d) ²⁷ and the high prevalence of preterm birth ⁴¹, the WHO
6
7 guideline may suitable for widespread implementation in our population. There is still a gap between
8
9 the calcium supplementation in Northwestern China and the WHO recommendation according to the
10
11 fact that more than 40% of women did not take calcium supplements during pregnancy, and only 11.7%
12
13 of the participants adhered to take calcium initiated from the second trimester for more than 90 total
14
15 days of use.
16
17

18
19 Evidence demonstrated that periconceptional MMN supplementation with iron and folic acid could
20
21 promote maternal health status, reduce the risk of LBW, SGA, and congenital abnormalities^{42,43}, as
22
23 well as improve the long-term intellectual development of the offspring ⁴⁴. Developed country like
24
25 Australia had a high prevalence of periconceptional MMS (79.2%) ³⁴, but the rate of MMS among
26
27 our participants was 14.0%. WHO did not universally recommend MMS for pregnant women due to
28
29 its potential neonatal mortality risks ¹¹, but the recent evidence from a meta-analysis of 17 randomized
30
31 control trials updated the WHO subgroup analysis and showed no increased risk of neonatal mortality
32
33 ⁴⁵, and the results are consistent with the findings of the 2017 Cochrane Review ⁴³. Moreover, the
34
35 2016 WHO guidelines stated that “policy-makers in populations with a high prevalence of nutritional
36
37 deficiencies might consider the benefits of MMS on maternal health to outweigh the disadvantages,
38
39 and may choose to give MMS that include iron and folic acid”. Consideration of situations including
40
41 high incidence of adverse birth outcomes, low intakes of most micronutrients from daily diet as well
42
43 as from supplement, and disadvantageous-sociodemographic conditions among many pregnant
44
45 women, the suggestion that to replace iron and folic acid with MMS for pregnant women in low-
46
47 income areas might be an useful strategy to comprehensively improve maternal micronutrient intake
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in this region ⁴³.

4
5 When examining the factors associated with the adherence to micronutrient supplementation, we
6
7 found that disadvantaged sociodemographic conditions and lower antenatal care were associated with
8
9 low adherence to micronutrient supplementation. Similar associations between education level and
10
11 prenatal health counseling with the adherence of micronutrient supplementation were reported in the
12
13 published literature ^{10,24,46}. Our finding of higher age and primiparity were the predictors of compliant
14
15 use of FA was consistent with the previous report in Ireland ⁴⁷. We did not find the relationship of the
16
17 type of hospitals for antenatal visits and FA supplementation, which may reflect the balanced
18
19 implementation of national health policy on maternal FA supplementation in the health system of the
20
21 study region. In our population, more times of antenatal visits were associated with higher adherence
22
23 of micronutrient supplementation. Besides routine obstetric examination, women accept the phased
24
25 health education from the physicians or specialized staff of maternal and child health care during the
26
27 antenatal care visits according to the gestation age. In addition, women planning to be pregnant or
28
29 being pregnant (before the 12 weeks of gestation) can receive free FA provided by the Chinese
30
31 government from the medical institutions when antenatal care visits and learn to appropriately use it
32
33 under the professional guidance. Iron or calcium supplementation are usually recommended to
34
35 pregnant women by physicians after the diagnosis of physical or pathological changes related to iron
36
37 or calcium deficiency. For women with severe pregnancy reactions or multiple-micronutrient
38
39 deficiency, the physician may recommend MMS. Thus, more times of antenatal care visits provide
40
41 more opportunities for women to learn the knowledge, and increase the possibilities for physicians to
42
43 know women's health condition and to give recommendations in time, which finally promotes the
44
45 adherence to micronutrient supplementation.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 To our knowledge, this is the first large-scale and representative study investigated the maternal
4
5 micronutrient supplementation in Northwestern China. A large sample of 28678 women were
6
7 recruited from twenty counties and ten districts of Shaanxi using a stratified multistage random
8
9 sampling method according to the proportion of rural to urban residents, population size and fertility
10
11 rate in Shaanxi. The results can serve as a data basis for developing health education strategies in the
12
13 future. Nonetheless, several limitations of the present study should be stated. First, this study was
14
15 retrospective and all the information of micronutrient supplementation was self-reported from
16
17 participants, and therefore the recall bias was ineluctable. Second, we did not provide an insight into
18
19 the dosage of use. Although we listed the possible brand of supplements that women might consume,
20
21 many women could only recall the micronutrient they used without clear commodity information.
22
23 Except for FA supplement of different brands usually have specified dosage of 400 µg per pill, the
24
25 specifications of other supplements are varied from each other, and thus it is hard to calculate the
26
27 accurate dosage used by our participants. But what is certain is that some supplements women
28
29 consumed were not specialized for pregnant women, and thus the content of elemental iron or calcium
30
31 in one tablet of the supplement is lower than the WHO recommended dosage, which may indicate the
32
33 more severe situation of low adherence of micronutrient supplementation in our population. Third,
34
35 the sources of recommendation regarding the use of supplements, as well as the access that women
36
37 procured the supplements, were not recorded. Hence, the approach that more proper for future
38
39 interventions could not be known. Finally, due to the diversities of economy, culture, lifestyle, as well
40
41 as eating habits in different geographical areas of China, the generalizability of our findings to other
42
43 geographical areas may be limited. More large-scale, in-depth and well-designed studies are
44
45 recommended to explore the effectiveness of supplementation of iron, calcium, and MMN on
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 pregnancy outcomes according to the adherence of use, and further promote the establishment of new
3
4
5 nutritional recommendation for pregnancy in China.
6
7
8
9

10 **Conclusion**

11
12 In conclusion, maternal micronutrient supplementation in Shaanxi failed to meet the Chinese
13
14 guideline and WHO recommendation according to initiation time and total days of use. Improving
15
16 the adherence to micronutrient supplementation before or during pregnancy is still a burning issue
17
18 for maternal and child health in Northwestern China. Targeted health education and future guidelines
19
20 of micronutrient supplementation are suggested to be implemented, especially for women with
21
22 disadvantaged sociodemographic conditions.
23
24
25
26
27
28
29
30

31 **Acknowledgments**

32
33 The authors are grateful to all women who took part in this research, all health staff who coordinated
34
35 fieldwork and all investigators who contributed to data collection.
36
37
38

39 **Ethics**

40
41 This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and
42
43 all procedures involving human subjects were approved by the Ethic Review Committee and
44
45 Academic Committee of Xi'an Jiaotong University Health Science Center (number 2012008).
46
47 Written informed consent was obtained from all participants.
48
49

50 **Funding**

51
52 This work was supported by the National Natural Science Foundation of China (grant number
53
54 81230016 and 81202218); and Shaanxi Health and Family Planning Commission (grant number
55
56 Sxwsjswzfcgght2016-013).
57
58
59
60

Competing interests

None.

Contributions

D.L., Y.C., L.Z., and H.Y. conceived and designed the study; D.L., S.L., F.L., B.M., R.Z., J.L. collected and cleared the data; D.L., D.W., Y.Z., C.L., S.L., F.L., and P.Q. analyzed and interpreted the data; D.L., Y.C., S.D., and L.Z. drafted and revised the manuscript. All authors read and approved the final version of the manuscript.

Data sharing statement

There is no additional data available.

For peer review only

Reference

1. Imdad A, Yakoob MY, Bhutta ZA. The effect of folic acid, protein energy and multiple micronutrient supplements in pregnancy on stillbirths. *Bmc Public Health*. 2011;**11 Suppl 3**:S4. doi:10.1186/1471-2458-11-s3-s4.
2. Branum AM, Bailey R, Singer BJ. Dietary supplement use and folate status during pregnancy in the United States. *J Nutr*. 2013;**143**:486-492. doi:10.3945/jn.112.169987.
3. Gernand AD, Schulze KJ, Stewart CP, West KP, Jr., Christian P. Micronutrient deficiencies in pregnancy worldwide: health effects and prevention. *Nat Rev Endocrinol*. 2016;**12**:274-289. doi:10.1038/nrendo.2016.37.
4. Tang L, Lee AH, Yau KKW, Hui YV, Binns CW. Consumption of dietary supplements by Chinese women during pregnancy and postpartum: A prospective cohort study. *Matern Child Nutr*. 2017;**13**. doi:10.1111/mcn.12435.
5. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev*. 2014:CD001059. doi:10.1002/14651858.CD001059.pub4.
6. Pena-Rosas JP, De-Regil LM, Garcia-Casal MN, Dowswell T. Daily oral iron supplementation during pregnancy. *Cochrane Database Syst Rev*. 2015:CD004736. doi:10.1002/14651858.CD004736.pub5.
7. De-Regil LM, Pena-Rosas JP, Fernandez-Gaxiola AC, Rayco-Solon P. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. *Cochrane Database Syst Rev*. 2015:CD007950. doi:10.1002/14651858.CD007950.pub3.
8. Li N, Li Z, Ye R, Liu J, Ren A. Impact of Periconceptional Folic Acid Supplementation on Low Birth Weight and Small-for-Gestational-Age Infants in China: A Large Prospective Cohort Study. *J Pediatr*. 2017;**187**:105-110. doi:10.1016/j.jpeds.2017.04.060.
9. Bibbins-Domingo K, Grossman DC, Curry SJ, *et al*. Folic Acid Supplementation for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2017;**317**:183-189. doi:10.1001/jama.2016.19438.
10. Teixeira JA, Castro TG, Wall CR, *et al*. Determinants of folic acid supplement use outside national recommendations for pregnant women: results from the Growing Up in New Zealand cohort study. *Public Health Nutr*. 2018:1-10. doi:10.1017/s1368980018000836.
11. WHO. *WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience*. Geneva, Switzerland: World Health Organization; 2016.
12. WHO. Prevention of neural tube defects *Standards for maternal and neonatal care*. 2007; Available at: https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/a91272/en/.
13. WHO. Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women. Geneva: World Health Organization; 2012.
14. WHO. Guideline: Calcium supplementation in pregnant women. Geneva: World Health Organization; 2013.
15. WHO. Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia. 2008:1-51.
16. Zeng L, Dibley MJ, Cheng Y, *et al*. Impact of micronutrient supplementation during pregnancy on birth weight, duration of gestation, and perinatal mortality in rural western China: double blind cluster randomised controlled trial. *Bmj*. 2008;**337**:a2001. doi:10.1136/bmj.a2001.
17. Berry RJ, Li Z, Erickson JD, *et al*. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. *N Engl J Med*. 1999;**341**:1485-1490. doi:10.1056/nejm199911113412001.
18. NHC of the People's Republic of China. Notifications on the issuance of "program of folic acid supplementation for the prevention of neural tube defects". 2009; Available at:

- 1
2 <http://www.nhfpc.gov.cn/tigs/s9660/200906/facb102b5c5a471788f8b8a8eed09a31.shtml>.
- 3
4 19. Chinese Nutrition Society. *Chinese Dietary Guidelines*. Tibet people's Press; 2013; 116-131.
- 5
6 20. Wang J, Zhao L, Piao J, Zhang J, Yang X, Yin S. [Nutrition and health status of pregnant women in 8 provinces
7 in China]. *Wei Sheng Yan Jiu*. 2011;**40**:201-203. doi.
- 8
9 21. Taye B, Abeje G, Mekonen A. Factors associated with compliance of prenatal iron folate supplementation among
10 women in Mecha district, Western Amhara: a cross-sectional study. *Pan Afr Med J*. 2015;**20**:43.
11 doi:10.11604/pamj.2015.20.43.4894.
- 12
13 22. Jasti S, Siega-Riz AM, Cogswell ME, Hartzema AG, Bentley ME. Pill count adherence to prenatal
14 multivitamin/mineral supplement use among low-income women. *J Nutr*. 2005;**135**:1093-1101.
15 doi:10.1093/jn/135.5.1093.
- 16
17 23. Nordeng H, Eskild A, Nesheim BI, Aursnes I, Jacobsen G. Guidelines for iron supplementation in pregnancy:
18 compliance among 431 parous Scandinavian women. *Eur J Clin Pharmacol*. 2003;**59**:163-168.
19 doi:10.1007/s00228-003-0599-x.
- 20
21 24. Gebreamlak B, Dadi AF, Atnafu A. High Adherence to Iron/Folic Acid Supplementation during Pregnancy Time
22 among Antenatal and Postnatal Care Attendant Mothers in Governmental Health Centers in Akaki Kality Sub
23 City, Addis Ababa, Ethiopia: Hierarchical Negative Binomial Poisson Regression. *Plos One*. 2017;**12**:e0169415.
24 doi:10.1371/journal.pone.0169415.
- 25
26 25. Kamau MW, Mirie W, Kimani S. Compliance with Iron and folic acid supplementation (IFAS) and associated
27 factors among pregnant women: results from a cross-sectional study in Kiambu County, Kenya. *Bmc Public
28 Health*. 2018;**18**:580. doi:10.1186/s12889-018-5437-2.
- 29
30 26. Cheng Y, Dibley MJ, Zhang X, Zeng L, Yan H. Assessment of dietary intake among pregnant women in a rural
31 area of western China. *Bmc Public Health*. 2009;**9**:222. doi:10.1186/1471-2458-9-222.
- 32
33 27. Yang J, Dang S, Cheng Y, *et al*. Dietary intakes and dietary patterns among pregnant women in Northwest China.
34 *Public Health Nutr*. 2017;**20**:282-293. doi:10.1017/s1368980016002159.
- 35
36 28. Yang J, Cheng Y, Pei L, *et al*. Maternal iron intake during pregnancy and birth outcomes: a cross-sectional study
37 in Northwest China. *Br J Nutr*. 2017;**117**:862-871. doi:10.1017/s0007114517000691.
- 38
39 29. Dang SN, Yan H, Xing Y. [Study on the level of hemoglobin and folate and anemia among women of
40 childbearing age in Shaanxi, China]. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2008;**29**:515-516. doi.
- 41
42 30. Wang LL, Bai RH, Liu Q, *et al*. [Epidemiological study on adverse pregnancy outcomes in Shaanxi province].
43 *Zhonghua Liu Xing Bing Xue Za Zhi*. 2016;**37**:1379-1382. doi:10.3760/ema.j.issn.0254-6450.2016.10.013.
- 44
45 31. Pei L, Kang Y, Cheng Y, Yan H. The Association of Maternal Lifestyle with Birth Defects in Shaanxi Province,
46 Northwest China. *Plos One*. 2015;**10**. doi:10.1371/journal.pone.0139452.
- 47
48 32. Sterne JA, White IR, Carlin JB, *et al*. Multiple imputation for missing data in epidemiological and clinical
49 research: potential and pitfalls. *Bmj*. 2009;**338**:b2393. doi:10.1136/bmj.b2393.
- 50
51 33. Hubbard AE, Ahern J, Fleischer NL, *et al*. To GEE or not to GEE: comparing population average and mixed
52 models for estimating the associations between neighborhood risk factors and health. *Epidemiology*.
53 2010;**21**:467-474. doi:10.1097/EDE.0b013e3181caeb90.
- 54
55 34. Shand AW, Walls M, Chatterjee R, Nassar N, Khambalia AZ. Dietary vitamin, mineral and herbal supplement
56 use: a cross-sectional survey of before and during pregnancy use in Sydney, Australia. *Australian & New
57 Zealand Journal of Obstetrics & Gynaecology*. 2016;**56**:154-161. doi:10.1111/ajo.12414.
- 58
59 35. Kim H, Jang W, Kim KN, *et al*. Comparison of dietary food and nutrient intakes by supplement use in pregnant
60 and lactating women in Seoul. *Nutr Res Pract*. 2013;**7**:199-206. doi:10.4162/nrp.2013.7.3.199.
36. Zhang Q, Wang Y, Xin X, *et al*. Effect of folic acid supplementation on preterm delivery and small for gestational
age births: A systematic review and meta-analysis. *Reproductive Toxicology*. 2017;**67**:35-41.
doi:10.1016/j.reprotox.2016.11.012.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
37. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. *Public Health Nutr.* 2009;**12**:444-454. doi:10.1017/s1368980008002401.
38. Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. *Bmj.* 2013;**346**:f3443. doi:10.1136/bmj.f3443.
39. Liu DM, Li JM, Qu PF, *et al.* [Prenatal supplementations of iron, iron-containing multimicronutrients and antianemic Chinese patent medicines in women in Shaanxi province, 2010-2013]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2017;**38**:1466-1470. doi:10.3760/cma.j.issn.0254-6450.2017.11.005.
40. Hofmeyr GJ, Lawrie TA, Atallah AN, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev.* 2018;**10**:Cd001059. doi:10.1002/14651858.CD001059.pub5.
41. Zou L, Wang X, Ruan Y, Li G, Chen Y, Zhang W. Preterm birth and neonatal mortality in China in 2011. *Int J Gynaecol Obstet.* 2014;**127**:243-247. doi:10.1016/j.ijgo.2014.06.018.
42. Czeizel AE. Periconceptional folic acid and multivitamin supplementation for the prevention of neural tube defects and other congenital abnormalities. *Birth Defects Research Part A Clinical and Molecular Teratology.* 2009;**85**:260-268. doi:10.1002/bdra.20563.
43. Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. *Cochrane Database of Systematic Reviews.* 2017;**4**:Cd004905. doi:10.1002/14651858.CD004905.pub5.
44. Zhu Z, Cheng Y, Zeng L, *et al.* Association of Antenatal Micronutrient Supplementation With Adolescent Intellectual Development in Rural Western China: 14-Year Follow-up From a Randomized Clinical Trial. *JAMA Pediatr.* 2018;**172**:832-841. doi:10.1001/jamapediatrics.2018.1401.
45. Sudfeld CR, Smith ER. New Evidence Should Inform WHO Guidelines on Multiple Micronutrient Supplementation in Pregnancy. *J Nutr.* 2019;**149**:359-361. doi:10.1093/jn/nxy279.
46. Bixenstine PJ, Cheng TL, Cheng D, Connor KA, Mistry KB. Association Between Preconception Counseling and Folic Acid Supplementation Before Pregnancy and Reasons for Non-Use. *Matern Child Health J.* 2015;**19**:1974-1984. doi:10.1007/s10995-015-1705-2.
47. Cawley S, Mullaney L, McKeating A, Farren M, McCartney D, Turner MJ. An analysis of folic acid supplementation in women presenting for antenatal care. *Journal of Public Health.* 2016;**38**:122-129. doi:10.1093/pubmed/fdv019.

Table 1 Maternal characteristics according to micronutrient supplementations among Chinese women in Shaanxi, 2010-2013

Characteristics	Micronutrient supplementations				<i>P</i> ^a
	Yes (n=24051)		No (n=4627)		
	<i>n</i>	%	<i>n</i>	%	
Sociodemographic characteristics					
Age (years)					<0.001
<25	7843	32.6	1615	34.9	
25-34	14299	59.5	2465	53.3	
≥35	1909	7.9	547	11.8	
Education					<0.001
Junior high school or below	14113	58.7	3611	78.0	
Senior high school	5114	21.3	627	13.6	
College or above	4824	20.0	389	8.4	
Geographic area					<0.001
Southern Shaanxi	5099	21.2	776	16.8	
Central Shaanxi	13731	57.1	1725	37.3	
Northern Shaanxi	5221	21.7	2126	45.9	
Residence					<0.001
Rural	15846	65.9	3455	74.7	
Urban	8205	34.1	1172	25.3	
Per capita annual household income (RMB)					<0.001
Low	7990	33.2	1714	37.0	
Medium	7819	32.5	1604	34.7	
High	8242	34.3	1309	28.3	
Birth history and antenatal care information					
Parity					<0.001
Primiparous	14651	60.9	2152	46.5	
Multiparous	9400	39.1	2475	53.5	
Pregnancy consultation ^b					<0.001
No	17404	72.4	3981	86.0	
Yes	6647	27.6	646	14.0	
The number of antenatal visits					<0.001
<5	6310	26.2	2298	49.7	
≥5	17741	73.8	2329	50.3	
Type of hospitals for antenatal visits					<0.001
Township hospitals	2783	11.6	622	13.4	
County hospitals or above	21268	88.4	4005	86.6	

^a *P* values for the differences among groups were derived from the χ^2 tests or Fisher's exact test.

^b Referred to the participation of health counselling that related to maternal healthcare and fetal development before or during pregnancy.

Table 2 Rates of maternal micronutrient supplementation among Chinese women in Shaanxi, 2010-2013

Micronutrient supplements	n	%
Folic acid	19352	67.6
Calcium	16414	57.5
Multiple micronutrient	4018	14.0
Iron	1547	5.4
Vitamin C	1147	4.0
B Vitamins	814	2.8
Vitamin E	173	0.6
Others ^a	1271	4.4

^a Including vitamin A, vitamin D and fish oil.

Table 3 Maternal micronutrient supplementation recommendations from WHO and CNS; rates of main micronutrient supplementation by initiation time and total days of use, and adherence to micronutrient supplementation among Chinese women in Shaanxi, 2010-2013

	FA (N=28629)	Iron (N=28644)	Calcium (N=28548)	MMN (N=28628)
Recommendations				
WHO recommendation	<p>1. Purpose: NTDs prevention Settings: all Supplementation: daily use of FA (400 µg) Duration: start at 2-month before the planned pregnancy until 12 weeks of pregnancy</p> <p>2. See recommendation for iron and FA supplementation in the right column</p>	<p>Purpose: pregnancy outcome improvement Settings: all Supplementation: daily use of iron (30-60 mg)-FA (400 µg) Duration: throughout pregnancy</p>	<p>Purpose: pre-eclampsia prevention Settings: areas with low calcium intake Supplementation: daily use of calcium (1.5-2.0 g) Duration: from 20 weeks' gestation until the end of pregnancy</p>	N/A
CNS recommendation	<p>Purpose: NTDs prevention and pregnancy outcome improvement Settings: all regions in China Supplementation: daily use of FA (400 µg) Duration: start at 3-month before the planned pregnancy until the end of pregnancy</p>	<p>No routine iron supplementation is recommended for pregnant women; Pregnant women with severe anemia should appropriately take iron supplements under the guidance of physicians</p>	N/A	N/A
Micronutrient supplementation in our population (n (%))				
Start at periconceptual period	18469 (64.5)	499 (1.7)	5292 (18.5)	1665 (5.8)
Start at 3-month before pregnancy	4966 (17.4)	79 (0.3)	272 (1.0)	212 (0.8)
< 90 days (180 days for FA)	3373 (11.8)	35 (0.1)	104 (0.4)	81 (0.3)
≥ 90 days (180 days for FA)	1593 (5.6)	44 (0.2)	168 (0.6)	131 (0.5)
Start at first trimester	13503 (47.2)	420 (1.5)	5020 (17.6)	1453 (5.1)

	< 90 days (180 days for FA)	12992 (45.4)	243 (0.9)	2291 (8.0)	683 (2.4)
	≥ 90 days (180 days for FA)	511 (1.8)	177 (0.6)	2729 (9.6)	770 (2.7)
Start at after-periconceptional period		883 (3.1)	1048 (3.7)	11122 (39.0)	2353 (8.2)
Start at second trimester		737 (2.6)	633 (2.2)	8947 (31.4)	1844 (6.4)
< 90 days		524 (1.8)	454 (1.6)	5614 (19.7)	1238 (4.3)
≥ 90 days		213 (0.7)	179 (0.6)	3333 (11.7)	606 (2.1)
Start at third trimester		146 (0.5)	415 (1.5)	2175 (7.6)	508 (1.8)
< 90 days		127 (0.4)	365 (1.3)	1810 (6.3)	435 (1.5)
≥ 90 days		19 (0.1)	50 (0.2)	365 (1.3)	73 (0.3)
Adherence to micronutrient supplementation (n (%))^a					
Non-adhered		26525 (92.7)	28467 (99.4)	25215 (88.3)	27858 (97.3)
Adhered		2104 (7.4)	177 (0.6)	3333 (11.7)	770 (2.7)

FA, folic acid; MMN, multiple-micronutrients; WHO, World Health Organization; CNS, Chinese Nutrition Society.

^a Adhered to FA supplementation was defined as initiated from the periconceptional period with ≥ 180 days of use, otherwise, was regarded as non-adhered; adhered to iron supplementation was considered as initiated from the first trimester with ≥ 90 days of use, otherwise, was regarded as non-adhered; adhered calcium supplementation was considered as initiated from the second trimester with ≥ 90 days of use, otherwise, was regarded as non-adhered; adhered to MMS was defined as initiated from the first trimester with ≥ 90 days of use, otherwise, was considered as non-adhered.

Table 4 Rates of adhered use of supplements by maternal characteristics and adjusted OR (95%CI) for factors associated to the adherence to micronutrient supplementation among Chinese women in Shaanxi, 2010-2013^a

Characteristics	n	FA		Iron		Calcium		MMN	
		Adhered use (%) ^b	Adjusted OR (95%CI)	Adhered use (%)	Adjusted OR (95%CI)	Adhered use (%)	Adjusted OR (95%CI)	Adhered use (%)	Adjusted OR (95%CI)
Sociodemographic characteristics (Model 1)^c									
Age (years)									
<25	9458	5.3	Ref	0.4	Ref	11.2	Ref	1.7	Ref
25-34	16764	8.7	1.30 (1.11, 1.52) *	0.7	1.49 (1.18, 1.88) *	12.4	1.03 (0.94, 1.12)	3.3	1.38 (1.12, 1.71) *
≥35	2456	6.3	1.22 (0.98, 1.51)	0.6	1.54 (0.80, 2.99)	8.6	0.71 (0.62, 0.81) *	2.3	1.24 (0.84, 1.84)
Education									
Junior high school or below	17724	4.9	Ref	0.4	Ref	9.9	Ref	1.6	Ref
Senior high school	5741	7.3	1.38 (1.18, 1.61) *	0.9	2.00 (1.36, 2.96) *	13.8	1.32 (1.22, 1.42) *	2.8	1.51 (1.21, 1.88) *
College or above	5213	15.9	2.59 (2.21, 3.05) *	1.2	1.69 (1.12, 2.54) *	15.5	1.45 (1.31, 1.60) *	6.2	2.65 (2.14, 3.28) *
Residence									
Rural	19301	5.9	Ref	0.4	Ref	10.6	Ref	2.1	Ref

1										
2										
3										
4										
5	Urban	9377	10.4	1.72 (1.08, 2.72) *	1.1	1.88 (1.17, 3.01) *	14.0	1.21 (0.90, 1.62)	3.9	1.30 (0.82, 2.06)
6										
7	Per capita annual household income (RMB)									
8										
9	Low	9689	5.0	Ref	0.4	Ref	10.6	Ref	1.8	Ref
10										
11	Medium	9402	6.4	1.07 (0.94, 1.23)	0.5	1.06 (0.74, 1.54)	11.7	1.08 (0.99, 1.19)	2.2	1.18 (0.96, 1.45)
12										
13	High	9538	10.7	1.27 (1.11, 1.45) *	1.0	1.56 (1.05, 2.32) *	12.8	1.09 (0.96, 1.24)	4.0	1.39 (1.11, 1.76) *
14										
15										
16	Birth history and antenatal care information (Model 2) ^d									
17										
18										
19	Parity									
20										
21	Primiparous	16803	9.2	Ref	0.7	Ref	12.8	Ref	3.2	Ref
22										
23	Multiparous	11875	4.8	0.70 (0.58, 0.84) *	0.5	0.90 (0.61, 1.34)	10.1	1.02 (0.94, 1.11)	1.9	0.88 (0.72, 1.07)
24										
25										
26	pregnancy consultation									
27										
28	No	21385	5.6	Ref	0.5	Ref	10.7	Ref	2.3	Ref
29										
30	Yes	7293	12.6	1.91 (1.71, 2.14) *	1.0	1.40 (1.21, 1.96) *	14.7	1.22 (1.10, 1.34) *	3.8	1.40 (1.17, 1.67) *
31										
32										
33										
34										
35	The number of antenatal visits									
36										
37										
38										
39										
40										
41										
42										
43										
44										
45										
46										

<5	8608	3.8	Ref	0.3	Ref	7.6	Ref	15.4	Ref
≥5	20070	8.9	1.59 (1.35, 1.87) *	0.8	1.66 (1.18, 2.34) *	13.4	1.41 (1.25, 1.60) *	26.4	1.33 (1.09, 1.62) *
Type of hospitals for antenatal visits									
Township hospitals	3405	5.9	Ref	0.5	Ref	9.6	Ref	1.7	Ref
County hospitals or above	25273	7.6	1.14 (0.94, 1.37)	0.6	1.26 (0.79, 2.01)	12.0	1.10 (0.94, 1.29)	2.8	1.14 (0.90, 1.46)

FA, folic acid; MMN, multiple-micronutrients; OR, odds ratio; CI, confident interval.

^a N=28678. The number of missing values for supplementation of FA, iron, calcium and MMN were 49, 34, 130 and 50. Adjusted OR and 95% CI were derived from multivariable GEE models with random effects at county level.

^b Adhered to FA supplementation was defined as initiated from the periconceptional period with ≥ 180 days of use; adhered to iron supplementation was considered as initiated from the first trimester with ≥ 90 days of use; adhered to calcium supplementation was considered as initiated from the second trimester with ≥ 90 days of use; adhered to MMS was defined as initiated from the first trimester with ≥ 90 days of use.

^c Model 1 adjusted for the sociodemographic characteristics including maternal age, education, residence and income, and the OR and 95% CI of these characteristics was derived from model 1.

^d Model 2 adjusted for all variables in model 1 plus parity and antenatal care characteristics, and the OR and 95% CI of parity and antenatal care characteristics was derived from model 2.

* Refers to $P < 0.05$.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-9
Bias	9	Describe any efforts to address potential sources of bias	7-9
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	None
		(c) Explain how missing data were addressed	9
		(d) If applicable, describe analytical methods taking account of sampling strategy	10
		(e) Describe any sensitivity analyses	None
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	None
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 3-4
Outcome data	15*	Report numbers of outcome events or summary measures	Table 1-4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 4
		(b) Report category boundaries when continuous variables were categorized	Table 1, Table 4
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	None
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	None
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	18

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Maternal adherence to micronutrient supplementation before and during pregnancy in Northwest China: a large-scale population-based cross-sectional survey

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028843.R2
Article Type:	Research
Date Submitted by the Author:	11-Jun-2019
Complete List of Authors:	<p>Liu, Danmeng; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Cheng, Yue; Xi'an Jiaotong University Health Science Center, Department of Nutrition Dang, Shaonong; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Wang, Duolao; Liverpool University, Liverpool School of Tropical Medicine Zhao, Yaling; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Li, Chao; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Li, Shanshan; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Lei, Fangliang; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Qu, Pengfei; Northwest women's and children's Hospital, Translational Medicine Center Mi, Baibing; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Zhang, Ruo; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Li, Jiamei; Department of Emergency Medicine, the Second Affiliated Hospital, Xi'an Jiaotong University, Department of Emergency Medicine Zeng, L; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics Yan, H; Xi'an Jiaotong University Health Science Center, Department of Epidemiology and Health Statistics; Nutrition and Food Safety Engineering Research Center of Shaanxi Province</p>
Primary Subject Heading:	Public health
Secondary Subject Heading:	Nutrition and metabolism, Obstetrics and gynaecology
Keywords:	Micronutrient supplementation, Pregnancy, Adherence, Associated factors

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Maternal adherence to micronutrient supplementation before and during pregnancy in**
4
5 **Northwest China: a large-scale population-based cross-sectional survey**
6
7
8
9

10 Danmeng Liu¹, Yue Cheng², Shaonong Dang¹, Duolao Wang³, Yaling Zhao¹, Chao Li¹, Shanshan
11
12 Li¹, Fangliang Lei¹, Pengfei Qu⁴, Baibing Mi¹, Ruo Zhang¹, Jiamei Li⁵, Lingxia Zeng¹*, Hong Yan¹

13
14
15 6 7 *

16
17
18
19
20
21 ¹Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong
22
23 University Health Science Center, No. 76 Yanta West Road, Xi'an, Shaanxi, 710061, China

24
25
26 ²Department of Nutrition, School of Public Health, Xi'an Jiaotong University Health Science Center,
27
28 No. 76 Yanta West Road, Xi'an, Shaanxi, 710061, China

29
30
31 ³Liverpool School of Tropical Medicine, Liverpool University, Pembroke Place, Liverpool, L3 5QA,
32
33 UK

34
35
36 ⁴Translational Medicine Center, Northwest women's and children's Hospital, No. 1616 Yanxiang
37
38 Road, Xi'an, Shaanxi, 710061, China

39
40
41 ⁵Department of Emergency Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University,
42
43 No. 157 West Fifth Road, Xi'an, Shaanxi, 710004, China

44
45
46
47 ⁶Nutrition and Food Safety Engineering Research Center of Shaanxi Province, Xi'an, Shaanxi,
48
49 710061, China

50
51
52 ⁷Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry
53
54 of Education, Xi'an, Shaanxi, 710061, China

55
56
57 *Corresponding author:
58
59
60

1
2
3 Lingxia Zeng, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China. Fax
4
5 +86 29 82655104, email tjzlx@mail.xjtu.edu.cn
6
7

8 Hong Yan, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China. Fax
9
10 +86 29 82655104, email xjtu_yh.paper@aliyun.com
11
12
13
14

15 **Abstract**

16
17
18 **Objectives:** To report the situation of maternal micronutrient supplementation before and during
19
20 pregnancy in Northwest China and to examine the rates of and factors related to the adherence to
21
22 micronutrient supplementation among pregnant women in this region, where dietary micronutrient
23
24 intake is commonly insufficient.
25
26

27
28 **Design:** A large-scale population-based cross-sectional survey.
29
30

31 **Setting:** Twenty counties and ten districts of Shaanxi Province.
32
33

34 **Participants:** A sample of 30,027 women were selected using a stratified multistage random
35
36 sampling method. A total of 28,678 women were chosen for the final analysis after excluding those
37
38 who did not provide clear information about nutritional supplementation before and during pregnancy.
39
40

41 **Main outcome measures:** Maternal adherence to micronutrient supplementation (high and low) were
42
43 the outcomes. They were determined by the start time and duration of use according to Chinese
44
45 guidelines (for folic acid [FA] supplements) and WHO recommendations (for iron, calcium, and
46
47 multiple-micronutrient [MMN] supplements).
48
49
50

51
52 **Results:** In total, 83.9% of women took at least one kind of micronutrient supplement before or during
53
54 pregnancy. FA (67.6%) and calcium (57.5%) were the primarily used micronutrient supplements; few
55
56 participants used MMN (14.0%) or iron (5.4%). Adherence to supplementation of all micronutrients
57
58
59
60

1
2
3 was low (7.4% for FA, 0.8% for iron, 23.2% for calcium and 3.2% for MMN). Higher educational
4
5 levels, higher income levels, urban residence, and better antenatal care (including pregnancy
6
7 consultation and a higher frequency of antenatal visits) were associated with high adherence to
8
9 micronutrient supplementation.
10
11

12
13 **Conclusion:** Maternal micronutrient supplementation before and during pregnancy in Northwest
14
15 China was way below standards recommended by the Chinese guidelines or WHO. Targeted health
16
17 education and future nutritional guidelines are suggested to improve this situation, especially in
18
19 pregnant women with disadvantaged sociodemographic conditions.
20
21
22

23
24
25
26 **Keywords:** Micronutrient supplementation; Pregnancy; Adherence; Associated factors
27

28
29 **Running Head:** Adherence to maternal micronutrient supplementation
30

31
32 **Word count:** 4192
33
34
35

36 37 **Strengths and limitations of this study**

- 38
39 • This is the first large-scale and representative study that vividly described maternal adherence to
40
41 micronutrient supplementation before and during pregnancy in Northwest China.
42
43
- 44
45 • Sample representativeness in Shaanxi was guaranteed by a large sample of 28,678 women that
46
47 were recruited using a stratified multistage random sampling method.
48
49
- 50
51 • The results could be generalized in Northwest China and may also reflect the universality of the
52
53 problem in China, and could serve as a basis for developing health education strategies in the
54
55 future.
56
57
- 58
59 • Recall bias was ineluctable because the information was self-reported by retrospection.
60

- The study does not provide an insight into the dosage of specific micronutrient supplementation due to the uncertain specifications of some reported supplements.

Introduction

Pregnancy is a state in which macro- and micronutrient requirements increase due to maternal physiological changes and fetal growth¹. During pregnancy, adequate micronutrient intake is difficult to achieve from daily diet², and maternal micronutrient deficiencies could cause severe adverse outcomes, including stillbirth, low birth weight (LBW), and birth defects³. Micronutrient supplementation is an alternative, in addition to the adjustment of diet pattern and quality, to fulfill the increased nutrition demands during pregnancy⁴. In recent decades, maternal micronutrient supplementation during pregnancy has attracted much attention, as growing evidence has shown that it has significant benefits in the improvement of maternal health status as well as birth outcomes⁵⁻⁸. As a result, some micronutrients that greatly contribute to maternal and fetal health are highly recommended for routine use during pregnancy. Many countries have implemented periconceptional folic acid (FA) supplementation to protect against neural tube defects (NTDs)^{9,10}. WHO has also provided several guidelines for micronutrient supplementation for pregnant women¹¹. Daily use of FA (400 µg), starting from 2 months before the planned pregnancy to 12 weeks of pregnancy is recommended for the prevention of NTDs¹²; daily oral FA combined with iron supplementation (400 µg FA and 30-60 mg iron) throughout pregnancy is recommended to reduce the risk of LBW, maternal anemia and iron deficiency¹³; daily oral calcium supplementation (1.5-2.0 g) in the second half of pregnancy is recommended for pregnant women in the area of low dietary calcium intake, to

1
2
3 reduce the risk of pre-eclampsia ¹⁴.
4

5
6 China is the most populated developing country with a considerable incidence of adverse
7 pregnancy outcomes, including maternal anemia ¹⁵, LBW ¹⁶, and small for gestational age ⁸. However,
8 the implementation of FA supplementation project (take daily FA (400 µg), start from 3 months
9 before pregnancy to the end of the first trimester) to prevent NTDs, especially in rural areas, is the
10 only nutritional intervention promoted by the Chinese Health Ministry (now the Chinese National
11 Health Commission) for pregnant women and women planning to be pregnant ^{17,18}. Also, the only
12 routine antenatal micronutrient supplementation recommended by the Chinese Nutrition Society
13 (CNS) for women of childbearing age is the daily use of FA (400 µg), starting from 3 months before
14 the planned pregnancy until the end of pregnancy ¹⁹. No more guidelines for routine supplementation
15 of other micronutrients exist, so that the use of micronutrient supplements during pregnancy varied
16 in Chinese geographic areas and socioeconomic groups ^{4,20}.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 All health policies and recommendations of micronutrient supplementation for pregnant women
35 emphasize the timing, dosage, sustainability of use, as well as the target population. Evidence showed
36 that low compliance was a major reason for the low effectiveness of micronutrient supplementation
37 during pregnancy ^{8,21}, and thus the exploration of the determinants of the adherence is important for
38 guiding the appropriate use to guarantee the efficacy. Many factors were reported in relation to
39 maternal adherence to micronutrient supplementation before and during pregnancy, including
40 maternal age, educational background, occupation, and antenatal care. Previous studies have reported
41 on the compliance of maternal micronutrient supplementation in Western countries like the United
42 States of American and Norway ^{22,23}, as well as in Africa countries like Ethiopia and Kenya ^{24,25}. Few
43 of the studies focused on maternal adherence to micronutrient supplementation before and during
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

pregnancy in China.

Shaanxi Province is a developing area in Northwest China where most of the micronutrients derived from diet among pregnant women were lower than the Chinese recommended nutrient intake (RNI)^{26,27}, especially the intake of folate and calcium^{26,27}. Although dietary iron intake was close to the RNI for the first and second trimester, most iron from diet were the non-heme iron, which is not efficiently absorbed and utilized by the human body²⁸. Additionally, about 40% of women of childbearing age in the region suffered anemia²⁹, and the incidence of adverse birth outcomes, including LBW and preterm birth, were high in this region³⁰. Therefore, maternal micronutrient supplementation seems to be a relatively inexpensive and low risk method for compensating for inadequate dietary intake during pregnancy and improving the health status of local mothers and fetus. However, a representative data from a large-scale study on the maternal micronutrient supplementation before and during pregnancy in this region is not available. Accordingly, this article aims to investigate the condition of maternal micronutrient supplementation before and during pregnancy in Shaanxi, focusing on analyzing the rates and associated factors of maternal adherence to supplement consumptions according to existing recommendations, and to provide evidence for future evaluation of health policy effectiveness and development of health education strategies.

Methods

Data source and participants

The study used data from a large-scale population-based cross-sectional survey, which was conducted between August to November 2013 in the Shaanxi province with the purpose of investigating the prevalence and risk factors of birth defects among newborns, along with maternal

1
2 dietary conditions and nutritional supplements use. The target population was women aged from 16
3
4
5 to 49 years, who were pregnant between 2010 to 2013 and had specific pregnancy outcomes before
6
7
8 the survey. The sample was acquired from 20 counties and 10 districts of Shaanxi by applying a
9
10 stratified multistage random sampling method ^{27,31}. Firstly, 20 counties and 10 districts were
11
12 randomly selected from the 80 rural counties and 24 urban districts in Shaanxi Province according to
13
14 the difference in size, distribution and fertility rates of population between rural and urban areas.
15
16 Subsequently, in the rural area, 6 townships, 6 villages, and 30 eligible women were randomly
17
18 selected from each sampled county, selected township, and selected village, respectively. In the urban
19
20 areas, 3 streets, 6 communities, and 60 eligible women were randomly selected from each sampled
21
22 district, selected street, and selected community, respectively. Data collection was completed with
23
24 structured-questionnaires via in-person surveys by trained interviewers. Information gathered
25
26 included maternal sociodemographic characteristics, lifestyle, health condition, health care utilization,
27
28 and supplement consumption. A strict quality control process was utilized to guarantee data integrity
29
30 and accuracy ²⁷.
31
32
33
34
35
36
37
38

39 A total of 30,027 women were enrolled in the survey after they signed the informed consent, and
40
41 women with limited cognitive capacity had been excluded. In order to obtain more accurate analysis
42
43 results, we further excluded 1,349 women who did not provide clear information about maternal
44
45 nutritional supplementation (among them, 761 women had no live birth babies in this pregnancy and
46
47 refused to provide detailed information). In total, 28,678 women were chosen for the final analysis.
48
49
50
51
52
53

54 **Maternal sociodemographic characteristics, parity, and antenatal care information**

55
56
57 Maternal age at delivery was divided into 3 categories (<25, 25-34 and ≥35 years), as well as
58
59
60

1
2
3 educational level (Junior high school or below, Senior high school and College and beyond),
4
5 geographical area (Southern Shaanxi, Central Shaanxi and Northern Shaanxi) and per capita annual
6
7 household income (Low: <8800, Medium: 8800-15200 and High: \geq 15200 Yuan, where 1
8
9 Yuan=\$0.149 on 17 Mar 2019). Residence (urban and rural) and parity (primiparous and multiparous)
10
11 were classified into 2 categories each. We also investigated the antenatal care information, including
12
13 the number of antenatal visits (<5 and \geq 5), the type of hospitals for antenatal visit (hospitals below
14
15 the county level and county level hospitals or above), and pregnancy consultation (yes and no,
16
17 referred to the participation of health counseling that related to maternal health care and fetal
18
19 development before or during pregnancy).
20
21
22
23
24
25
26
27

28 **Micronutrient supplementation**

29
30 Information about micronutrient supplements in tablet and capsule forms were mainly collected.
31
32 We asked the participants to choose the supplements they used before or during pregnancy from a list
33
34 of brands of supplements that were commonly provided in the local hospital or pharmacy, and to
35
36 further tell the brand and kind of supplement they consumed, if it was not shown in the list. We did
37
38 not list iron-FA supplements in the questionnaire, since few supplements on the market were two-
39
40 nutrient formulations of iron and FA. In the analysis, FA supplements referred to those that only
41
42 contained FA; iron supplements referred to those that only contained iron; calcium supplements
43
44 referred to those that contained calcium or calcium with another micronutrient (including calcium-
45
46 vitamin D and calcium-zinc); multiple-micronutrient (MMN) supplements referred to those that
47
48 contained FA, iron, and other micronutrients. Women who consumed any micronutrient supplement
49
50 before or during pregnancy were considered as micronutrient supplement users; otherwise, were
51
52
53
54
55
56
57
58
59
60

1
2
3 regarded as non-users.
4

5 We further obtained the time and duration of use of each supplement they reported. The
6
7 participants were required to select the time of supplement use from the 4 pregnancy periods (3
8 months before the last menstrual period, the first trimester, the second trimester, and the third
9 trimester) and report the duration of supplementation for each supplement they used. The 3 months
10 before the last menstrual period was defined as the pre-conceptual period; the time from the 3
11 months before the last menstrual period to the end of first trimester was defined as the
12 periconceptual period; the time of the second and third trimester was defined as the after-
13 periconceptual period.
14
15
16
17
18
19
20
21
22
23
24

25 Adherence to micronutrient supplementation before and during pregnancy was determined by
26 the start time and duration of use according to Chinese guidelines (for FA) and WHO
27 recommendations (for iron, calcium, and MMN). Although WHO did not universally recommend
28 MMN supplementation (MMS) for pregnant women, due to its components of iron and FA, we still
29 examined the compliance of MMS by referencing the WHO recommendation for iron and FA
30 supplementation. We considered the duration of use instead of the total amounts, because most of the
31 supplements of interest were taken as 1 tablet daily. In the present study, the thresholds used to define
32 the adhered duration of use were 180 days for FA and 90 days for others. Therefore, high adherence
33 to FA supplementation was defined as starting from the periconceptual period with ≥ 180 days of
34 use; otherwise, was regarded as low adherence. High adherence to iron supplementation was
35 considered as starting from the first trimester with ≥ 90 days of use; otherwise, was regarded as low
36 adherence. For calcium supplementation, 20 weeks of gestation was the start time recommended by
37 WHO. Since we did not collect the specific weeks of gestation of micronutrient supplementation,
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 high adherence to calcium supplementation was considered as starting from the second trimester with
3
4
5 ≥ 90 days of use; otherwise, was regarded as low adherence. High adherence to MMS was defined as
6
7
8 one starting from the first trimester with ≥ 90 days of use; otherwise, was considered as low adherence.
9

10 11 12 13 **Statistical analysis**

14
15 Dataset was established using Epidata 3.1 (The Epidata Association, Odense, Denmark) with
16
17 double entry. Multiple imputation was used to attribute values for the missing variables, including
18
19 income level (n=5830), maternal age group (n=434), and the type of hospital for antenatal visits
20
21 (n=327), taking education level, geographic area, residence, parity, the number of antenatal visits,
22
23 and pregnancy consultation as covariates with 5 imputed data sets ³². Numbers and percentages (n
24
25 [%]) were estimated for reporting the rate of micronutrient supplementation in different groups and
26
27 for presenting the adherence to micronutrient supplementation. Comparisons between groups were
28
29 completed by either the Chi-square test or Fisher's exact test.
30
31
32
33
34
35

36
37 Because of the hierarchical structure of the data derived from the stratified multistage random
38
39 sampling design, multivariable generalized estimating equation (GEE) models ³³ with random effect
40
41 at county level were applied to estimate adjusted odds ratio (OR) and 95% confidence interval (CI)
42
43 for factors associated with maternal adherence to micronutrient supplementation before and during
44
45 pregnancy. Maternal characteristics including age, education, residence, income, parity, pregnancy
46
47 consultation, number of antenatal visits, and type of hospital for antenatal visits were the fixed effects
48
49 in the GEE models. Binomial distribution, logit link function, and an exchangeable covariance
50
51 structure were used in the GEE analysis. Model 1 analyzed the relationship between the adherence to
52
53 micronutrient supplementation and the sociodemographic characteristics including age, education,
54
55
56
57
58
59
60

1
2 residence, and income. Model 2 analyzed the relationship between the adherence to micronutrient
3 supplementation and sociodemographic characteristics (all the variables in model 1), as well as parity
4 and antenatal care characteristics. The criteria for statistical significance was $P < 0.05$. All analyses
5 were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
6
7
8
9
10
11
12
13
14

15 **Patient and public involvement**

16
17 No patients were involved in developing the research question, outcome measure and design of
18 the study. We were unable to disseminate the results of the research directly to study participants, and
19 we informed the results to the local health authorities.
20
21
22
23
24
25
26
27

28 **Results**

29 **Maternal characteristics according to micronutrient supplementation before and during** 30 **pregnancy**

31
32 Significant differences existed in aspects of maternal sociodemographic conditions, birth history,
33 and antenatal care characteristics between users and non-users of micronutrient supplements before
34 and during pregnancy (**Table 1**). Users of micronutrient supplements were more likely to be aged
35 from 25 to 34 years, be better educated, have higher income level, live in central Shaanxi live, be
36 rural residents, be primiparous, and have better antenatal care (including pregnancy consultations,
37 higher-level hospital for antenatal visits, and a higher frequency of antenatal visits).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **Rates of and the adherence to micronutrient supplementation before and during pregnancy**

55
56 In total, 83.9% of women took at least one kind of micronutrient supplement before or during
57
58
59
60

1
2
3 their last pregnancy. The main supplements used by participants were folic acid (FA) (67.6%),
4
5 calcium (57.5%), MMN (14.0%), and iron (5.4%) (**Table 2**). Although FA had a relatively higher
6
7 rate of use during the periconceptual period (64.5%), only 7.4% of women continued usage from
8
9 the periconceptual period for longer than 180 days. Most of the users started taking calcium
10
11 supplements during the second trimester (39%), but only 11.7% met the recommended standards after
12
13 taking the duration of use into consideration. Comparing to the rates of those who began to use iron
14
15 or MMN in the after-periconceptual period (3.7% for iron, and 8.2% for MMN), smaller proportion
16
17 of women commenced consumption from the first trimester (1.7% for iron, and 5.8% for MMN), and
18
19 few of them adhered to use of iron or MMN in more than 90 days (0.6% for iron, and 2.7% for MMN).
20
21 (**Table 3**). We also found that very few women (0.2%) consumed FA and iron starting from the first
22
23 trimester with more than 90 days of use (not shown in table). We further examined the adherence to
24
25 supplementation of FA, iron, and FA with iron by taking the contribution of MMS into consideration.
26
27 Still, the rates of compliant use were low (8.5% for FA, 3.2% for iron, and 2.9% for FA with iron,
28
29 not shown in table).
30
31
32
33
34
35
36
37
38
39
40
41

42 **Factors associated with the adherence to micronutrient supplementation before and during** 43 **pregnancy** 44 45

46 **Table 4** shows the results of multivariable GEE models. Higher educational levels (for example:
47
48 FA: Senior high school vs. Junior high school or below: OR 1.38, 95% CI 1.18, 1.61; College and
49
50 beyond vs. Junior high school or below: OR 2.59, 95% CI 2.21, 3.05), higher income levels (for
51
52 example: FA: High vs. Low: OR 1.27, 95% CI 1.11, 1.45), urban residence (for example: FA: Urban
53
54 vs. Rural: OR 1.72, 95% CI 1.08, 2.72), and better antenatal care (including pregnancy consultation
55
56
57
58
59
60

1
2 [for example: FA: Yes vs. No: OR 1.91, 95% CI 1.71, 2.14] and a higher frequency of antenatal visits
3
4 [for example: FA: ≥ 5 times vs. < 5 times: OR 1.59, 95% CI 1.35, 1.87]) were associated with high
5
6 adherence to micronutrient supplementation before and during pregnancy. Compared with women
7
8 below 25 years, women aged from 25 to 34 years were more likely to have high adherence to the
9
10 supplementation of FA (OR 1.30, 95% CI 1.11, 1.52), iron (OR 1.49 95% CI 1.18, 1.88), and MMN
11
12 (OR 1.38, 95% CI 1.12, 1.71). Women above 35 years were associated with a lower probability of
13
14 high adherence to calcium supplementation (OR 0.71, 95% CI 0.62, 0.81). Being multipara was less
15
16 likely related to high adherence to FA supplementation (OR 0.70, 95% CI 0.58, 0.84). The type of
17
18 hospital for antenatal visits was not linked to the adherence to micronutrient supplementation.
19
20
21
22
23
24
25
26
27
28

29 Discussion

30
31 In this large-scale cross-sectional study, we observed that micronutrient supplements were not
32
33 used as commonly as expected before and during pregnancy, and maternal adherence to micronutrient
34
35 supplementation among our population, particularly in women with sociodemographic-disadvantages,
36
37 were low based on the CNS and WHO recommendations. Totally, the prevalence of maternal
38
39 micronutrient supplementation before and during pregnancy in Shaanxi from 2010 to 2013 was 83.9%.
40
41 Compared with other countries, our overall use rate was higher than that of United States from 1999
42
43 to 2006 (77.6%)², but lower than those of Sydney, Australia in 2014 (93.8%)³⁴ and Seoul, Korea in
44
45 2012 (88%)³⁵. Compared with the domestic data, it was similar to that of Sichuan Province (81.8%)
46
47 in 2010⁴ and higher than the overall prevalence of 8 Provinces of China in 2009 (66.4%)²⁰. FA,
48
49 calcium, MMN, and iron were the four supplements primarily used by participants.
50
51
52
53
54
55

56
57 Maternal FA supplementation is associated with the prevention of NTDs as well as the reduced
58
59
60

1
2 risk of preterm delivery and small for gestational age (SGA) births³⁶. Both WHO and CNS developed
3
4 guidelines for promoting daily FA supplementation before and during pregnancy^{13,19}, and the
5
6 Chinese government also implemented the periconceptual FA supplementation to prevent NTDs
7
8 since 2009. In our population, FA was the most popularly used supplement before and during
9
10 pregnancy, but more than 30% of women still did not take it. Additionally, most of the users started
11
12 to take FA supplements after they became pregnant, and only few took FA supplements to prepare
13
14 for pregnancy, which may indicate the high frequency of unplanned pregnancies or the lack of
15
16 knowledge about pre-conceptual FA supplementation. The more serious reality was that less than
17
18 10% of women adhered to FA supplementation periconceptionally in more than 180 days. Therefore,
19
20 the use of FA supplements failed to reach the recommended standards among pregnant women in
21
22 Northwest China, even when maternal routine FA supplementation was strongly promoted in China.
23
24
25
26
27
28
29
30

31 China has a high prevalence of pregnancy anemia, which is commonly caused by iron deficiency
32
33 during pregnancy^{15,37}. Reviews stated that daily iron supplementation in pregnancy could be useful
34
35 in improving iron status and birth outcomes^{6,38}. Only 5.4% of the participants consumed iron
36
37 supplements during pregnancy, and the low rate of iron supplementation was possibly attributed to
38
39 the lack of routine maternal iron supplementation guidelines in China and the popular use of anti-
40
41 anemic Chinese patent medicines among pregnant women in this region³⁹. The proportion of women
42
43 who had compliant iron supplementation was very low in our population (0.6% for iron and 3.2% for
44
45 iron and iron-containing MMS), which is much lower than that of Western Amhara of Ethiopia (20.4%
46
47 for FA-iron)²¹. On the basis of the WHO recommendation, maternal iron supplementation should be
48
49 started as early as possible during pregnancy¹³. Our participants usually began to use iron
50
51 supplements after the periconceptual period rather than from the beginning of pregnancy. The
52
53
54
55
56
57
58
59
60

1
2
3 reason may be that most women only took iron supplements under the direction of physicians after
4
5 the occurrence of iron deficiency or iron deficiency anemia during the second half of pregnancy, but
6
7 prophylactic supplementation was very rare.
8
9

10 Maternal calcium supplementation has a clear beneficial effect on hypertension-related disorders
11
12 during pregnancy and is possibly related to the reduction of preterm birth risk ⁴⁰. To prevent pre-
13
14 eclampsia, WHO recommends daily calcium supplementation from 20 weeks of gestation for
15
16 populations with low dietary calcium intake ¹⁴. From the background of the low dietary calcium intake
17
18 among pregnant women (512 mg/d) ²⁷ and the high prevalence of preterm birth ⁴¹, the WHO guideline
19
20 may be suitable for widespread implementation in our population. A gap still exists between calcium
21
22 supplementation among pregnant women in Northwest China and the WHO recommendation,
23
24 according to the fact that more than 40% of women did not take calcium supplements during
25
26 pregnancy and only 11.7% of the participants adhered to take calcium right from the start of the
27
28 second trimester for more than 90 days of use.
29
30
31
32
33
34
35

36 Evidence demonstrated that periconceptional MMN supplementation with iron and folic acid
37
38 could promote maternal health status, reduce the risk of LBW, SGA, and congenital abnormalities^{42,43},
39
40 as well as improve the long-term intellectual development of offspring ⁴⁴. Developed countries like
41
42 Australia had a high prevalence of periconceptional MMS (79.2%) ³⁴, but the rate of MMS among
43
44 our participants was 14.0%. WHO did not universally recommend MMS for pregnant women due to
45
46 its potential neonatal mortality risks ¹¹, but the recent evidence showed no increased risk of neonatal
47
48 mortality ^{43,45}. Moreover, the 2016 WHO guidelines stated that “policy-makers in populations with a
49
50 high prevalence of nutritional deficiencies might consider the benefits of MMS on maternal health to
51
52 outweigh the disadvantages, and may choose to give MMS that include iron and folic acid”.
53
54
55
56
57
58
59
60

1
2
3 Comprehensively taking the situations of Shaanxi (including high incidence of adverse birth
4
5 outcomes, low intake of most micronutrients from daily diet as well as from supplements, and
6
7 disadvantaged sociodemographic conditions among many pregnant women) into consideration, to
8
9 replace iron and folic acid with MMS for pregnant women in low-income areas might be a useful
10
11 strategy to improve overall maternal micronutrient intake in this region ⁴³.
12
13

14
15 When examining the factors associated with maternal adherence to micronutrient
16
17 supplementation before and during pregnancy, we found that sociodemographic disadvantages and
18
19 lower antenatal care level were associated with low adherence to micronutrient supplementation.
20
21 Similar associations between educational level and prenatal health counseling with adherence to
22
23 micronutrient supplementation were reported in literature ^{10,24,46}. Our finding that higher age and
24
25 primiparity were predictors of compliant use of FA was consistent with that of a previous study in
26
27 Ireland ⁴⁷. We did not find any relationship between the type of hospital for antenatal visits and FA
28
29 supplementation, which may reflect the balanced implementation of national health policy on
30
31 maternal FA supplementation in the health system of the study region. In our population, higher
32
33 frequency of antenatal visits was associated with higher adherence to micronutrient supplementation.
34
35 Aside from routine obstetric examination, women accept the phased health education from the
36
37 physicians during their antenatal care visits. In addition, women planning to be pregnant or are
38
39 pregnant (before 12 weeks of gestation) can receive free FA provided by the Chinese government
40
41 during antenatal care visits and learn to appropriately use them under professional guidance. Iron or
42
43 calcium supplementation is usually recommended to pregnant women by physicians after the
44
45 diagnosis of physical or pathological changes related to iron or calcium deficiency. For women with
46
47 severe pregnancy reactions or multiple-micronutrient deficiency, the physician may recommend
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 MMS. Thus, higher frequency of antenatal care visits provides more opportunities for women to learn,
4
5 and increases the possibilities for physicians to know the pregnant women's health condition and to
6
7 give recommendations in time, which finally promotes the adherence to micronutrient
8
9 supplementation.
10
11

12
13 To the best of our knowledge, this is the first large-scale and representative study that
14
15 investigated maternal micronutrient supplementation before and during pregnancy in Northwest
16
17 China. To guarantee the representativeness, a large sample was recruited from Shaanxi Province of
18
19 Northwest China using a stratified multistage random sampling method according to the proportion
20
21 of rural to urban residents, population size and fertility rate in the region. The results could be
22
23 generalized to other regions in Northwest China according to the similarities in terms of economy,
24
25 culture, lifestyle and diet habits existing in these regions, and may also reflect the universality of the
26
27 low adherence to micronutrient supplementation before and during pregnancy in China. Therefore, it
28
29 could serve as a basis for developing health education strategies in the future. Nonetheless, several
30
31 limitations of the present study should be stated. First, this study was retrospective, and all the
32
33 information of micronutrient supplementation was self-reported from participants, and therefore
34
35 recall bias was ineluctable. Second, we did not provide an insight into the dosage of use. Although
36
37 we listed the possible brands of supplements that women might consume, many women could only
38
39 recall the micronutrient they used without clear commodity information. Except for FA supplements,
40
41 which usually have specified dosage of 400 µg per pill, the specifications of other supplements vary
42
43 from each other, and thus it is difficult to calculate the accurate dosage used by our participants.
44
45 However, what is certain is that some supplements women consumed were not specialized for
46
47 pregnant women, and thus the content of elemental iron or calcium in one tablet of the supplement is
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 lower than the WHO recommended dosage, which may indicate the more severe situation of low
4
5 adherence of micronutrient supplementation in our population. Third, the sources of recommendation
6
7 regarding the use of supplements, as well as the access that women procured the supplements, were
8
9 not recorded. Hence, the approach for more appropriate future interventions could not be known.
10
11 More large-scale, in-depth, and well-designed studies are recommended to explore the effectiveness
12
13 of supplementation of iron, calcium, and MMN on pregnancy outcomes according to the adherence
14
15 of use, and further promote the establishment of new nutritional recommendations for pregnancy in
16
17 China.
18
19
20
21
22
23
24
25

26 **Conclusion**

27
28 In conclusion, maternal micronutrient supplementation before and during pregnancy in Shaanxi
29
30 failed to meet the Chinese guidelines and WHO recommendation, with respect to start time and
31
32 duration of use. Improving the adherence to micronutrient supplementation before or during
33
34 pregnancy is still a dire issue for maternal and child health in Northwest China. Targeted health
35
36 education and future guidelines of micronutrient supplementation for pregnant women should be
37
38 implemented, especially for those with disadvantaged sociodemographic conditions.
39
40
41
42
43
44
45
46

47 **Acknowledgments**

48 The authors are grateful to all women who took part in this research, all health staff who
49
50 coordinated fieldwork and all investigators who contributed to data collection.
51
52
53

54 **Ethics**

55 This study was conducted according to the guidelines laid down in the Declaration of Helsinki,
56
57 and all procedures involving human subjects were approved by the Ethic Review Committee and
58
59
60

1
2 Academic Committee of Xi'an Jiaotong University Health Science Center (number 2012008).
3
4 Written informed consent was obtained from all participants.
5
6
7

8 **Funding**

9
10 This work was supported by the National Natural Science Foundation of China (grant number
11 81230016 and 81202218); and Shaanxi Health and Family Planning Commission (grant number
12 Sxwsjswzfcgght2016-013).
13
14
15
16

17 **Competing interests**

18 None.
19
20
21
22

23 **Contributions**

24 D.L., Y.C., L.Z., and H.Y. conceived and designed the study; D.L., S.L., F.L., B.M., R.Z., J.L.
25 collected and cleared the data; D.L., D.W., Y.Z., C.L., S.L., F.L., and P.Q. analyzed and interpreted
26 the data; D.L., Y.C., S.D., and L.Z. drafted and revised the manuscript. All authors read and approved
27 the final version of the manuscript.
28
29
30
31
32
33

34 **Data sharing statement**

35 There is no additional data available.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Imdad A, Yakoob MY, Bhutta ZA. The effect of folic acid, protein energy and multiple micronutrient supplements in pregnancy on stillbirths. *Bmc Public Health*. 2011;**11 Suppl 3**:S4. doi:10.1186/1471-2458-11-s3-s4.
2. Branum AM, Bailey R, Singer BJ. Dietary supplement use and folate status during pregnancy in the United States. *J Nutr*. 2013;**143**:486-492. doi:10.3945/jn.112.169987.
3. Gernand AD, Schulze KJ, Stewart CP, West KP, Jr., Christian P. Micronutrient deficiencies in pregnancy worldwide: health effects and prevention. *Nat Rev Endocrinol*. 2016;**12**:274-289. doi:10.1038/nrendo.2016.37.
4. Tang L, Lee AH, Yau KKW, Hui YV, Binns CW. Consumption of dietary supplements by Chinese women during pregnancy and postpartum: A prospective cohort study. *Matern Child Nutr*. 2017;**13**. doi:10.1111/mcn.12435.
5. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev*. 2014:CD001059. doi:10.1002/14651858.CD001059.pub4.
6. Pena-Rosas JP, De-Regil LM, Garcia-Casal MN, Dowswell T. Daily oral iron supplementation during pregnancy. *Cochrane Database Syst Rev*. 2015:CD004736. doi:10.1002/14651858.CD004736.pub5.
7. De-Regil LM, Pena-Rosas JP, Fernandez-Gaxiola AC, Rayco-Solon P. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. *Cochrane Database Syst Rev*. 2015:CD007950. doi:10.1002/14651858.CD007950.pub3.
8. Li N, Li Z, Ye R, Liu J, Ren A. Impact of Periconceptional Folic Acid Supplementation on Low Birth Weight and Small-for-Gestational-Age Infants in China: A Large Prospective Cohort Study. *J Pediatr*. 2017;**187**:105-110. doi:10.1016/j.jpeds.2017.04.060.
9. Bibbins-Domingo K, Grossman DC, Curry SJ, *et al*. Folic Acid Supplementation for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2017;**317**:183-189. doi:10.1001/jama.2016.19438.
10. Teixeira JA, Castro TG, Wall CR, *et al*. Determinants of folic acid supplement use outside national recommendations for pregnant women: results from the Growing Up in New Zealand cohort study. *Public Health Nutr*. 2018:1-10. doi:10.1017/s1368980018000836.
11. WHO. *WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience*. Geneva, Switzerland: World Health Organization; 2016.
12. WHO. Prevention of neural tube defects *Standards for maternal and neonatal care*. 2007; Available at: https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/a91272/en/.
13. WHO. Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women. Geneva: World Health Organization; 2012.
14. WHO. Guideline: Calcium supplementation in pregnant women. Geneva: World Health Organization; 2013.
15. WHO. Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia. 2008:1-51.
16. Zeng L, Dibley MJ, Cheng Y, *et al*. Impact of micronutrient supplementation during pregnancy on birth weight, duration of gestation, and perinatal mortality in rural western China: double blind cluster randomised controlled trial. *Bmj*. 2008;**337**:a2001. doi:10.1136/bmj.a2001.
17. Berry RJ, Li Z, Erickson JD, *et al*. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. *N Engl J Med*. 1999;**341**:1485-1490. doi:10.1056/nejm199911113412001.
18. NHC of the People's Republic of China. Notifications on the issuance of "program of folic acid supplementation for the prevention of neural tube defects". 2009; Available at:

- 1
2 <http://www.nhfpc.gov.cn/tigs/s9660/200906/facb102b5c5a471788f8b8a8eed09a31.shtml>.
- 3
4 19. Chinese Nutrition Society. *Chinese Dietary Guidelines*. Tibet people's Press; 2013; 116-131.
- 5
6 20. Wang J, Zhao L, Piao J, Zhang J, Yang X, Yin S. [Nutrition and health status of pregnant women in 8 provinces
7 in China]. *Wei Sheng Yan Jiu*. 2011;**40**:201-203. doi.
- 8
9 21. Taye B, Abeje G, Mekonen A. Factors associated with compliance of prenatal iron folate supplementation among
10 women in Mecha district, Western Amhara: a cross-sectional study. *Pan Afr Med J*. 2015;**20**:43.
11 doi:10.11604/pamj.2015.20.43.4894.
- 12
13 22. Jasti S, Siega-Riz AM, Cogswell ME, Hartzema AG, Bentley ME. Pill count adherence to prenatal
14 multivitamin/mineral supplement use among low-income women. *J Nutr*. 2005;**135**:1093-1101.
15 doi:10.1093/jn/135.5.1093.
- 16
17 23. Nordeng H, Eskild A, Nesheim BI, Aursnes I, Jacobsen G. Guidelines for iron supplementation in pregnancy:
18 compliance among 431 parous Scandinavian women. *Eur J Clin Pharmacol*. 2003;**59**:163-168.
19 doi:10.1007/s00228-003-0599-x.
- 20
21 24. Gebreamlak B, Dadi AF, Atnafu A. High Adherence to Iron/Folic Acid Supplementation during Pregnancy Time
22 among Antenatal and Postnatal Care Attendant Mothers in Governmental Health Centers in Akaki Kality Sub
23 City, Addis Ababa, Ethiopia: Hierarchical Negative Binomial Poisson Regression. *Plos One*. 2017;**12**:e0169415.
24 doi:10.1371/journal.pone.0169415.
- 25
26 25. Kamau MW, Mirie W, Kimani S. Compliance with Iron and folic acid supplementation (IFAS) and associated
27 factors among pregnant women: results from a cross-sectional study in Kiambu County, Kenya. *Bmc Public
28 Health*. 2018;**18**:580. doi:10.1186/s12889-018-5437-2.
- 29
30 26. Cheng Y, Dibley MJ, Zhang X, Zeng L, Yan H. Assessment of dietary intake among pregnant women in a rural
31 area of western China. *Bmc Public Health*. 2009;**9**:222. doi:10.1186/1471-2458-9-222.
- 32
33 27. Yang J, Dang S, Cheng Y, *et al*. Dietary intakes and dietary patterns among pregnant women in Northwest China.
34 *Public Health Nutr*. 2017;**20**:282-293. doi:10.1017/s1368980016002159.
- 35
36 28. Yang J, Cheng Y, Pei L, *et al*. Maternal iron intake during pregnancy and birth outcomes: a cross-sectional study
37 in Northwest China. *Br J Nutr*. 2017;**117**:862-871. doi:10.1017/s0007114517000691.
- 38
39 29. Dang SN, Yan H, Xing Y. [Study on the level of hemoglobin and folate and anemia among women of
40 childbearing age in Shaanxi, China]. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2008;**29**:515-516. doi.
- 41
42 30. Wang LL, Bai RH, Liu Q, *et al*. [Epidemiological study on adverse pregnancy outcomes in Shaanxi province].
43 *Zhonghua Liu Xing Bing Xue Za Zhi*. 2016;**37**:1379-1382. doi:10.3760/ema.j.issn.0254-6450.2016.10.013.
- 44
45 31. Pei L, Kang Y, Cheng Y, Yan H. The Association of Maternal Lifestyle with Birth Defects in Shaanxi Province,
46 Northwest China. *Plos One*. 2015;**10**. doi:10.1371/journal.pone.0139452.
- 47
48 32. Sterne JA, White IR, Carlin JB, *et al*. Multiple imputation for missing data in epidemiological and clinical
49 research: potential and pitfalls. *Bmj*. 2009;**338**:b2393. doi:10.1136/bmj.b2393.
- 50
51 33. Hubbard AE, Ahern J, Fleischer NL, *et al*. To GEE or not to GEE: comparing population average and mixed
52 models for estimating the associations between neighborhood risk factors and health. *Epidemiology*.
53 2010;**21**:467-474. doi:10.1097/EDE.0b013e3181caeb90.
- 54
55 34. Shand AW, Walls M, Chatterjee R, Nassar N, Khambalia AZ. Dietary vitamin, mineral and herbal supplement
56 use: a cross-sectional survey of before and during pregnancy use in Sydney, Australia. *Australian & New
57 Zealand Journal of Obstetrics & Gynaecology*. 2016;**56**:154-161. doi:10.1111/ajo.12414.
- 58
59 35. Kim H, Jang W, Kim KN, *et al*. Comparison of dietary food and nutrient intakes by supplement use in pregnant
60 and lactating women in Seoul. *Nutr Res Pract*. 2013;**7**:199-206. doi:10.4162/nrp.2013.7.3.199.
36. Zhang Q, Wang Y, Xin X, *et al*. Effect of folic acid supplementation on preterm delivery and small for gestational
age births: A systematic review and meta-analysis. *Reproductive Toxicology*. 2017;**67**:35-41.
doi:10.1016/j.reprotox.2016.11.012.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

37. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. *Public Health Nutr.* 2009;**12**:444-454. doi:10.1017/s1368980008002401.
38. Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. *Bmj.* 2013;**346**:f3443. doi:10.1136/bmj.f3443.
39. Liu DM, Li JM, Qu PF, *et al.* [Prenatal supplementations of iron, iron-containing multimicronutrients and antianemic Chinese patent medicines in women in Shaanxi province, 2010-2013]. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2017;**38**:1466-1470. doi:10.3760/cma.j.issn.0254-6450.2017.11.005.
40. Hofmeyr GJ, Lawrie TA, Atallah AN, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev.* 2018;**10**:Cd001059. doi:10.1002/14651858.CD001059.pub5.
41. Zou L, Wang X, Ruan Y, Li G, Chen Y, Zhang W. Preterm birth and neonatal mortality in China in 2011. *Int J Gynaecol Obstet.* 2014;**127**:243-247. doi:10.1016/j.ijgo.2014.06.018.
42. Czeizel AE. Periconceptional folic acid and multivitamin supplementation for the prevention of neural tube defects and other congenital abnormalities. *Birth Defects Research Part A Clinical and Molecular Teratology.* 2009;**85**:260-268. doi:10.1002/bdra.20563.
43. Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. *Cochrane Database of Systematic Reviews.* 2017;**4**:Cd004905. doi:10.1002/14651858.CD004905.pub5.
44. Zhu Z, Cheng Y, Zeng L, *et al.* Association of Antenatal Micronutrient Supplementation With Adolescent Intellectual Development in Rural Western China: 14-Year Follow-up From a Randomized Clinical Trial. *JAMA Pediatr.* 2018;**172**:832-841. doi:10.1001/jamapediatrics.2018.1401.
45. Sudfeld CR, Smith ER. New Evidence Should Inform WHO Guidelines on Multiple Micronutrient Supplementation in Pregnancy. *J Nutr.* 2019;**149**:359-361. doi:10.1093/jn/nxy279.
46. Bixenstine PJ, Cheng TL, Cheng D, Connor KA, Mistry KB. Association Between Preconception Counseling and Folic Acid Supplementation Before Pregnancy and Reasons for Non-Use. *Matern Child Health J.* 2015;**19**:1974-1984. doi:10.1007/s10995-015-1705-2.
47. Cawley S, Mullaney L, McKeating A, Farren M, McCartney D, Turner MJ. An analysis of folic acid supplementation in women presenting for antenatal care. *Journal of Public Health.* 2016;**38**:122-129. doi:10.1093/pubmed/fdv019.

Table 1 Maternal characteristics according to micronutrient supplementation before and during pregnancy among Chinese women in Shaanxi, 2010-2013

Characteristics	Micronutrient supplementation				<i>P</i> ^a
	Yes (n=24051)		No (n=4627)		
	<i>n</i>	%	<i>n</i>	%	
Sociodemographic characteristics					
Age (years)					<0.001
<25	7843	32.6	1615	34.9	
25-34	14299	59.5	2465	53.3	
≥35	1909	7.9	547	11.8	
Education					<0.001
Junior high school or below	14113	58.7	3611	78.0	
Senior high school	5114	21.3	627	13.6	
College and beyond	4824	20.0	389	8.4	
Geographic area					<0.001
Southern Shaanxi	5099	21.2	776	16.8	
Central Shaanxi	13731	57.1	1725	37.3	
Northern Shaanxi	5221	21.7	2126	45.9	
Residence					<0.001
Rural	15846	65.9	3455	74.7	
Urban	8205	34.1	1172	25.3	
Per capita annual household income (RMB)					<0.001
Low	7990	33.2	1714	37.0	
Medium	7819	32.5	1604	34.7	
High	8242	34.3	1309	28.3	
Birth history and antenatal care information					
Parity					<0.001
Primiparous	14651	60.9	2152	46.5	
Multiparous	9400	39.1	2475	53.5	
Pregnancy consultation ^b					<0.001
No	17404	72.4	3981	86.0	
Yes	6647	27.6	646	14.0	
The number of antenatal visits					<0.001
<5	6310	26.2	2298	49.7	
≥5	17741	73.8	2329	50.3	
Type of hospitals for antenatal visits					<0.001
Township hospitals	2783	11.6	622	13.4	
County hospitals or above	21268	88.4	4005	86.6	

^a *P* values for the differences among groups were derived from either the χ^2 tests or Fisher's exact test.

^b Referred to the participation of health counselling that related to maternal healthcare and fetal development before or during pregnancy.

Table 2 Rates of maternal micronutrient supplementation before and during pregnancy among Chinese women in Shaanxi, 2010-2013

Micronutrient supplements	n	%
Folic acid	19352	67.6
Calcium	16414	57.5
Multiple micronutrient	4018	14.0
Iron	1547	5.4
Vitamin C	1147	4.0
B Vitamins	814	2.8
Vitamin E	173	0.6
Others ^a	1271	4.4

^a Including vitamin A, vitamin D and fish oil.

Table 3 Maternal micronutrient supplementation recommendations from WHO and CNS; rates of main micronutrient supplementation by start time and duration of use, and adherence to micronutrient supplementation before and during pregnancy among Chinese women in Shaanxi, 2010-2013

	FA (N=28629)	Iron (N=28644)	Calcium (N=28548)	MMN (N=28628)
Recommendations				
WHO recommendation	<p>1. Purpose: NTDs prevention Settings: all Supplementation: daily use of FA (400 µg) Duration: start at 2-month before the planned pregnancy until 12 weeks of pregnancy</p> <p>2. See recommendation for iron and FA supplementation in the right column</p>	<p>Purpose: pregnancy outcome improvement Settings: all Supplementation: daily use of iron (30-60 mg)-FA (400 µg) Duration: throughout pregnancy</p>	<p>Purpose: pre-eclampsia prevention Settings: areas with low calcium intake Supplementation: daily use of calcium (1.5-2.0 g) Duration: from 20 weeks' gestation until the end of pregnancy</p>	N/A
CNS recommendation	<p>Purpose: NTDs prevention and pregnancy outcome improvement Settings: all regions in China Supplementation: daily use of FA (400 µg) Duration: start at 3-month before the planned pregnancy until the end of pregnancy</p>	<p>No routine iron supplementation is recommended for pregnant women; Pregnant women with severe anemia should appropriately take iron supplements under the guidance of physicians</p>	N/A	N/A
Micronutrient supplementation in our population (n (%))				
Start at periconceptual period	18469 (64.5)	499 (1.7)	5292 (18.5)	1665 (5.8)
Start at 3-month before pregnancy	4966 (17.4)	79 (0.3)	272 (1.0)	212 (0.8)
< 90 days (180 days for FA)	3373 (11.8)	35 (0.1)	104 (0.4)	81 (0.3)
≥ 90 days (180 days for FA)	1593 (5.6)	44 (0.2)	168 (0.6)	131 (0.5)
Start at first trimester	13503 (47.2)	420 (1.5)	5020 (17.6)	1453 (5.1)

< 90 days (180 days for FA)	12992 (45.4)	243 (0.9)	2291 (8.0)	683 (2.4)
≥ 90 days (180 days for FA)	511 (1.8)	177 (0.6)	2729 (9.6)	770 (2.7)
Start at after-periconceptional period	883 (3.1)	1048 (3.7)	11122 (39.0)	2353 (8.2)
Start at second trimester	737 (2.6)	633 (2.2)	8947 (31.4)	1844 (6.4)
< 90 days	524 (1.8)	454 (1.6)	5614 (19.7)	1238 (4.3)
≥ 90 days	213 (0.7)	179 (0.6)	3333 (11.7)	606 (2.1)
Start at third trimester	146 (0.5)	415 (1.5)	2175 (7.6)	508 (1.8)
< 90 days	127 (0.4)	365 (1.3)	1810 (6.3)	435 (1.5)
≥ 90 days	19 (0.1)	50 (0.2)	365 (1.3)	73 (0.3)
Adherence to micronutrient supplementation (n (%))^a				
Low adherence	26525 (92.7)	28467 (99.4)	25215 (88.3)	27858 (97.3)
High adherence	2104 (7.4)	177 (0.6)	3333 (11.7)	770 (2.7)

FA, folic acid; MMN, multiple-micronutrients; WHO, World Health Organization; CNS, Chinese Nutrition Society.

^a High adherence to FA supplementation was defined as starting from the periconceptional period with ≥ 180 days of use; otherwise, was regarded as low adherence. High adherence to iron supplementation was considered as starting from the first trimester with ≥ 90 days of use; otherwise, was regarded as low adherence. High adherence to calcium supplementation was considered as starting from the second trimester with ≥ 90 days of use; otherwise, was regarded as low adherence. High adherence to MMS was defined as starting from the first trimester with ≥ 90 days of use; otherwise, was considered as low adherence.

Table 4 Rates of high adherence to micronutrient supplementation before and during pregnancy by maternal characteristics and adjusted OR (95%CI) for factors associated to the high adherence among Chinese women in Shaanxi, 2010-2013^a

Characteristics	n	FA		Iron		Calcium		MMN	
		High adherence (%) ^b	Adjusted OR (95%CI)	High adherence (%)	Adjusted OR (95%CI)	High adherence (%)	Adjusted OR (95%CI)	High adherence (%)	Adjusted OR (95%CI)
Sociodemographic characteristics (Model 1)^c									
Age (years)									
<25	9458	5.3	Ref	0.4	Ref	11.2	Ref	1.7	Ref
25-34	16764	8.7	1.30 (1.11, 1.52) *	0.7	1.49 (1.18, 1.88) *	12.4	1.03 (0.94, 1.12)	3.3	1.38 (1.12, 1.71) *
≥35	2456	6.3	1.22 (0.98, 1.51)	0.6	1.54 (0.80, 2.99)	8.6	0.71 (0.62, 0.81) *	2.3	1.24 (0.84, 1.84)
Education									
Junior high school or below	17724	4.9	Ref	0.4	Ref	9.9	Ref	1.6	Ref
Senior high school	5741	7.3	1.38 (1.18, 1.61) *	0.9	2.00 (1.36, 2.96) *	13.8	1.32 (1.22, 1.42) *	2.8	1.51 (1.21, 1.88) *
College and beyond	5213	15.9	2.59 (2.21, 3.05) *	1.2	1.69 (1.12, 2.54) *	15.5	1.45 (1.31, 1.60) *	6.2	2.65 (2.14, 3.28) *
Residence									

	19301	5.9	Ref	0.4	Ref	10.6	Ref	2.1	Ref
Rural									
	9377	10.4	1.72 (1.08, 2.72) *	1.1	1.88 (1.17, 3.01) *	14.0	1.21 (0.90, 1.62)	3.9	1.30 (0.82, 2.06)
Urban									
Per capita annual household income (RMB)									
	9689	5.0	Ref	0.4	Ref	10.6	Ref	1.8	Ref
Low									
	9402	6.4	1.07 (0.94, 1.23)	0.5	1.06 (0.74, 1.54)	11.7	1.08 (0.99, 1.19)	2.2	1.18 (0.96, 1.45)
Medium									
	9538	10.7	1.27 (1.11, 1.45) *	1.0	1.56 (1.05, 2.32) *	12.8	1.09 (0.96, 1.24)	4.0	1.39 (1.11, 1.76) *
High									
Birth history and antenatal care information (Model 2) ^d									
Parity									
	16803	9.2	Ref	0.7	Ref	12.8	Ref	3.2	Ref
Primiparous									
	11875	4.8	0.70 (0.58, 0.84) *	0.5	0.90 (0.61, 1.34)	10.1	1.02 (0.94, 1.11)	1.9	0.88 (0.72, 1.07)
Multiparous									
pregnancy consultation									
	21385	5.6	Ref	0.5	Ref	10.7	Ref	2.3	Ref
No									
	7293	12.6	1.91 (1.71, 2.14) *	1.0	1.40 (1.21, 1.96) *	14.7	1.22 (1.10, 1.34) *	3.8	1.40 (1.17, 1.67) *
Yes									

The number of antenatal visits

<5	8608	3.8	Ref	0.3	Ref	7.6	Ref	15.4	Ref
≥5	20070	8.9	1.59 (1.35, 1.87) *	0.8	1.66 (1.18, 2.34) *	13.4	1.41 (1.25, 1.60) *	26.4	1.33 (1.09, 1.62) *
Type of hospitals for antenatal visits									
Township hospitals	3405	5.9	Ref	0.5	Ref	9.6	Ref	1.7	Ref
County hospitals or above	25273	7.6	1.14 (0.94, 1.37)	0.6	1.26 (0.79, 2.01)	12.0	1.10 (0.94, 1.29)	2.8	1.14 (0.90, 1.46)

FA, folic acid; MMN, multiple-micronutrients; OR, odds ratio; CI, confident interval.

^a N=28678. The number of missing values for supplementation of FA, iron, calcium and MMN were 49, 34, 130 and 50. Adjusted OR and 95% CI were derived from multivariable GEE models with random effects at county level.

^b High adherence to FA supplementation was defined as starting from the periconceptional period with ≥ 180 days of use; high adherence to iron supplementation was considered as starting from the first trimester with ≥ 90 days of use; high adherence to calcium supplementation was considered as starting from the second trimester with ≥ 90 days of use; high adherence to MMS was defined as starting from the first trimester with ≥ 90 days of use.

^c Model 1 adjusted for the sociodemographic characteristics including maternal age, education, residence and income, and the OR and 95% CI of these characteristics was derived from model 1.

^d Model 2 adjusted for all variables in model 1 plus parity and antenatal care characteristics, and the OR and 95% CI of parity and antenatal care characteristics was derived from model 2.

* Refers to $P < 0.05$.

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-9
Bias	9	Describe any efforts to address potential sources of bias	7-9
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	None
		(c) Explain how missing data were addressed	9
		(d) If applicable, describe analytical methods taking account of sampling strategy	10
		(e) Describe any sensitivity analyses	None
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	None
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 3-4
Outcome data	15*	Report numbers of outcome events or summary measures	Table 1-4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 4
		(b) Report category boundaries when continuous variables were categorized	Table 1, Table 4
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	None
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	None
Discussion			
Key results	18	Summarise key results with reference to study objectives	12-13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	18

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.